EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
 
 
 
 
 
 
 
EPI[INVESTIGATOR_266014],  INC. 
 
 
CLINICAL  STUDY  PROTOCOL  
 
 
A Phase  1, Prospective  Safety  Trial of  EPN-701 in Subjects  with Stable  End Stage 
Renal Disease (ESRD) Receiving Outpatient Hemodialysis  
 
 
Protocol  Number:  EPN-701-001 
IND Number: 129344  
 
Amendment  3, Dated  January  16, 2020  
Replaces  Protocol  Version:  Amendment  2, Dated:  March  23, 2019  
 
 
 
 
 
Sponsor:  Epi[INVESTIGATOR_266015],  Inc. 
[ADDRESS_323649] 
[LOCATION_001], NY [ZIP_CODE] 
Telephone: +[PHONE_5498]  
Facsimile:  +[PHONE_5499]  
 
 
 
 
CONFIDENTIALITY  
This document contains confidential information belonging to Epi[INVESTIGATOR_266016], Inc., and is provided to you in 
confidence as an investigator, potential investigator, or consultant, for review by [CONTACT_10825], your staff, and the 
reviewing Ethics Committee or Institutional Review Board. Except as otherwise agreed to in writing, by 
[CONTACT_266041],  you agree  to hold this information  in confidence  and not copy  or disclose 
it to others (except where required by [CONTACT_2371]) or use it for unauthorized purposes. In the event of any actual or 
suspected breach of this obligation, Epi[INVESTIGATOR_266017].  
 
 
Protocol  Number:  EPN-701-001, Amendment  3 1 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
1. SPONSOR  SIGNATORIES  
 
 
SPONSOR:  John  M. Rudey,  Chairman  
Epi[INVESTIGATOR_266015] , Inc. 
[ADDRESS_323650] 
[LOCATION_001],  NY [ZIP_CODE],  [LOCATION_003]  
Telephone:  [PHONE_5515] .9900  
Email: [EMAIL_5117]   
 
 
 
Date  
 
 
Chief  Operating  Officer  
Epi[INVESTIGATOR_266015],  Inc. 
[ADDRESS_323651],  Suite  90B 
[LOCATION_001],  NY [ZIP_CODE], [LOCATION_003] 
Telephone:  +1.50B.487.0830  
E-mail: [EMAIL_5118]  
 
 
 
 
Date  
 
SPONSOR'S 
MEDICAL 
REPRESENTAT IVE: James A. Tumlin,  MD 
Founder  and Director  of Nephronet  Clinical  Trials  Consortium  
[ADDRESS_323652] 
Atlanta,  GA [ZIP_CODE],  [LOCATION_003] 
 
Telephone : +[PHONE_5500]  
 
 
 
 
 
Date  
 
 
 
 
 
 
 
 
Protocol  Number.  EPN-701·001,  Amendment  3 2 
 
 
 
 
iam E. Gannon  Jr., MD 
Email:  jamestumllnmdnephronet  

EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 3  
  
 
2. INVESTIGATOR  AGREEMENT  
 
 
TITLE:  A Phase  1, Prospective  Safety  Trial of EPN-701 in Subjects 
with Stable End Stage Renal Disease (ESRD) Receiving 
Outpatient Hemodialysis  
PROTOCOL NUMBER:  EPN-701-001 
VERSION  NUMBER:  6.0 (Amendment  3) 
VERSION  DATE:  January  16, 2020  
IND NUMBER:  [ADDRESS_323653]:  EPN-701 
SPONSOR:  Epi[INVESTIGATOR_266015],  Inc. 
I agree  to conduct  this clinical  trial according  to the protocol  described  herein,  and to comply  with 
its requirements, subject to ethical and safety considerations and guidelines. I also agree to 
conduct this study in compliance with Good Clinical  Practice (GCP) standards as defined by  [CONTACT_20417]  (ICH) Guideline for Good Clinical Practice, all 
applicable national, state, and local regulations, as well as the requirements of the appropriate 
Institutional Review Board/Independent Ethics Committee (IRB/IEC) and any other institutional 
requirements.  
I understand that the information in this protocol is confidential and should not be disclosed to 
others  without  written  authorization  from Epi[INVESTIGATOR_266015],  Inc., except  to the extent  necessary  to: 
(1) obtain  informed  consent  from persons  to whom the  drug may be administered;  and (2) inform 
those directly involved in the execution or the scientific/ethical review of the study.  
I understand that failure to comply with the requirements of the protocol may lead to my 
participation as an Investigator for this study to be terminated.  
 
 
 
Principal  Investigator’s  Name  (print)    
Principal  Investigator’s  Signature   [CONTACT_266112]. Please  return  a copy  of the signed 
form as instructed by [CONTACT_266042] (CRA).  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 4  
  
 
3. STUDY  ADMINISTRATIVE  STRUCTURE  
 
RESPONSIBILITY  NAME  & CONTACT  [CONTACT_266043]  / 
Study Medical Monitor  Katherine  M. Smith,  MD 
[ADDRESS_323654] 
Raleigh, NC [ZIP_CODE]  
Telephone:  +[PHONE_5501]  
E-mail:  [EMAIL_5119]  
Independent  Medical  Monitor  J. Bruce  McClain,  MD 
[ADDRESS_323655]  
Lovettsville,  VA [ZIP_CODE]  
Mobile:  +[PHONE_5502]  
E-mail:  [EMAIL_5120]  
Safety  Reporting  
and Pharmacovigilance  Analysis  MedAssessment,  Inc. 
14 Calle  Vista  Del Sol 
San Clemente,  CA [ZIP_CODE] -6913  
Telephone: +[PHONE_5503] 
Website:  www.medassessment.com  
Contract  Research  Organization 
(CRO)  NephroSynergy,  LLC 
[ADDRESS_323656] 
Lawrenceville,  GA [ZIP_CODE]  
Telephone:  +[PHONE_5504]  
Fax: +[PHONE_5505]  
Email:  [EMAIL_5121]  
Central  Laboratory  
(Safety  Laboratory,  Biomarker,  and 
PK Assessments)  
 
 
 
 
Biomarker Laboratories 
(PI[INVESTIGATOR_266018] -II, dp-ucMGP,  and T-50; 
Respectively)  Covance  Central  Laboratory  Services 
[ADDRESS_323657]  
Indianapolis,  Indiana  [ZIP_CODE]  
Telephone:  +[PHONE_5506]  
Fax: +[PHONE_5507]  
Website:  www.covance.com  
 
Ventana Medical Systems, Inc 
Pharma Services Laboratory 
[ADDRESS_323658] 
Tucson, AZ  [ZIP_CODE]  
Telephone: +[PHONE_5508] 
Email:  [EMAIL_5122]  
 
University  of Liège  – Dept.  of Chemistry 
Bone & Cartilage Markers Laboratory 
Hospi[INVESTIGATOR_266019] B35  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 5  
  
 
RESPONSIBILITY  NAME  & CONTACT  [CONTACT_266044]  52, Porte  52 
4000  Liège 
Belgium  
Telephone:  +00.[PHONE_5509]  
Email:  anne -[EMAIL_5123]  
 
Calciscon  AG 
Aarbergstrasse  5 
2560  Nidau 
Switzerland  
Telephone:  [PHONE_5516]  
Email:  [EMAIL_5124]  
Study  Drug  Packaging,  Labeling, 
and Distribution  Sherpa  Clinical  Packaging  dba PCI Pharma  Services 
[ADDRESS_323659]  
San Diego, CA [ZIP_CODE] 
Telephone:  +[PHONE_5510]  
Website:  SherpaClinical.com  
Institutional  Review  Board  Copernicus  Group  IRB 
[ADDRESS_323660] 
Cary  NC [ZIP_CODE]  
Telephone:  +[PHONE_5511]  
Facsimile: +[PHONE_5512] 
Email:  [EMAIL_5125]  
Website:  www.wcgclinical.com  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323661]  of Hemodialysis  ................................ . 25 
6.1.2  Long -Active  Derivatives  of Vitamin  K2: Therapeutic  role for 
Menaquinone -7 ................................ ................................ ............................  29 
6.2 Background  on EPN-701................................ ................................ ....................  30 
6.2.1  Summary  of Nonclinical  Studies  ................................ ................................ ... 30 
6.2.2  Summary  of Clinical  Studies  of EPN-701 ................................ ......................  31 
6.2.3  Clinical  Pharmacokinetics  of EPN-701................................ ..........................  32 
6.2.4  Anticipated  Risks  Associated  with EPN-701 ................................ .................  32 
6.2.5  Benefit -Risk Assessment  ................................ ................................ ..............  33 
6.3 Rationale  for the Study  and Study  Design  ................................ ..........................  33 
6.3.1  Rationale  for the Study  and Study  Population  ................................ ...............  33 
6.3.2  Rationale  for the EPN-701 Dose  and Schedule  ................................ ............  33 
6.3.3  Rationale  for Biomarker  Assessments  ................................ ..........................  34 
7. OBJECTIVES  AND  ENDPOINTS  ................................ ................................ ............  35 
8. STUDY  DESIGN  ................................ ................................ ................................ ...... 38 
8.1 Description  of the Study  ................................ ................................ .....................  38 
8.1.1  Schedule  of Assessments  ................................ ................................ ............  39 
8.1.2  Study  Committees  ................................ ................................ ........................  39 
8.2 End of Study  and Length  of Study  ................................ ................................ ...... 39 
9. MATERIALS  AND  METHODS  ................................ ................................ .................  40 
9.1 Subjects  ................................ ................................ ................................ .............  40 
9.1.1  Inclusion  Criteria ................................ ................................ ...........................  40 
9.1.2  Exclusion  Criteria  ................................ ................................ .........................  40 
9.2 Method  of Treatment  Assignment  and Blinding  ................................ ..................  41 
9.2.1  Randomization  and Blinding  ................................ ................................ .........  41 
9.2.2  Treatment  Assignment  ................................ ................................ .................  41 
9.3 Study  Drug:  EPN-701 ................................ ................................ .........................  41 
9.3.1  Description  of the Study  Drug ................................ ................................ ....... 42 
9.3.2  Study  Drug  Packaging,  Storage,  and Handling  ................................ .............  42 
9.3.3  Study  Drug Labeling  ................................ ................................ .....................  42 
9.3.4  Study  Drug Dispensing  ................................ ................................ .................  43 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323662]-Trial Access  to EPN-701 ................................ ................................ ...... 44 
9.4 Concomitant  Therapy  ................................ ................................ .........................  44 
9.4.1  Prohibited  Therapy  ................................ ................................ .......................  45 
9.4.2  Prohibited  Food  ................................ ................................ ............................  45 
9.5 Study  Visits  ................................ ................................ ................................ ........  45 
9.5.1  Screening  Visit (Day  -7 to Day -1) ................................ ................................  46 
9.5.2  Visit 1 (Day  1, Baseline),  Visit 4 (Day  8), Visit 7 (Day  15, End-of- 
Treatment),  and Visit 10 (Day  22) [Mondays]  ................................ ................  47 
9.5.3  Visits  2 & 3 (Days  3 & 5), Visits  5 & 6 (Days  10 & 12), Visits  8 & 9 
(Days  17 & 19), and Visits  11 & 12 (Days  24 & 26) [Wednesdays  & 
Fridays]  ................................ ................................ ................................ ........  48 
9.5.4  End-of-Study/Early  Termination  Visit (Day  29) ................................ ..............  [ADDRESS_323663]  Log ................................ ...................  48 
9.6.2  Medical  History  and Demographic  Data  Collection  ................................ ....... 49 
9.6.3  Baseline  and Concomitant  Medications  ................................ ........................  49 
9.6.4  Physical  Examinations  and Measurements ................................ ...................  49 
9.6.5  Vital Signs  Measurements  ................................ ................................ ............  49 
9.6.6  Electrocardiograms  ................................ ................................ .......................  49 
9.6.7  Assessment  of Dialysis  Adequacy  (Kt/V)  ................................ ......................  [ADDRESS_323664],  Site, and Study  Discontinuation  ................................ ..........  54 
9.7.1  Study  Drug Discontinuation  ................................ ................................ ..........  54 
9.7.2  Withdrawal  of Subjects  from the Study  ................................ .........................  54 
9.7.3  Study  Discontinuation  ................................ ................................ ...................  55 
9.7.4  Site Discontinuation  ................................ ................................ ......................  55 
10. ASSESSMENT  OF SAFETY  ................................ ................................ ...................  55 
10.1 Definitions  ................................ ................................ ................................ ..........  55 
10.2 Overall  Safety  Plan ................................ ................................ ............................  57 
10.2.1  Dose  Modifications  and Interruptions  due to Adverse  Events  .......................  58 
10.3 Recording  and Assessment  of Adverse  Events  ................................ ..................  58 
10.3.1  Adverse  Event  Recording  and Reporting  Period  ................................ ...........  58 
10.3.2  Adverse  Event  Recording  Guidelines  ................................ ...........................  58 
10.3.3  Assessment  of Adverse Events  ................................ ................................ .... 59 
10.3.4  Adverse  Event  Follow -up Period ................................ ................................ ... 61 
10.4 Immediate  Reporting  Requirements  ................................ ................................ ... 62 
10.4.1  Immediately  Reportable  Events  ................................ ................................ .... 62 
10.4.2  Reporting  Requirements  for SAEs  and AESIs  ................................ ..............  62 
10.4.3  Reporting  Requirements  for Pregnancies  ................................ .....................  63 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323665]  Confidentiality  ................................ ................................ ........................  71 
14. STUDY  DOCUMENTATION  ................................ ................................ ....................  71 
14.1 Study  Documentation  ................................ ................................ .........................  71 
14.2 Protocol  Amendments  ................................ ................................ ........................  71 
14.3 Protocol  Deviations  ................................ ................................ ............................  72 
14.4 Publication  Policy  ................................ ................................ ...............................  72 
15. REFERENCES  ................................ ................................ ................................ ........  73 
16. APPENDIX 1 - DEFINITION AND CLASSIFICATION OF CHRONIC KIDNEY  
DISEASE (CKD)  ................................ ................................ ................................ ..... 78 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323666]  OF FIGURES  
 
Figure  1 – Vitamin  K Cycle  ................................ ................................ ................................ .. 26 
Figure  2 – The Carboxylation  of Protein  Residues  Serine  and Threonine  ............................  28 
Figure  3 – In vivo Plasma  Protein  Carbonyl  Formation  ................................ ........................  28 
Figure  4 – Vitamin  K Structures  ................................ ................................ ...........................  29 
Figure  5 – Sequence  of PK Sampling,  Visits  1 – 8 ................................ ...............................  53 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323667]  research  organization  
CUA Calcific  Uremic  Arteriolopathy  (calciphylaxis)  
CVA cerebrovascular  accident  
dba 
DNA doing business as 
deoxyribonucleic  acid 
dp-cMGP  desphospho -carboxylated  Matrix  Gla Protein  
dp-ucMGP  dephosphorylated  and uncarboxylated  Matrix  Gla Protein  
eCRF  electronic  Case  Report  Form  
ECG Electrocardiogram  
EDC electronic  data capture  
EFSA  European  Food  Safety  Authority  
EOS End-of-Study  (visit)  
EOT End-of-Treatment  (visit)  
ESRD  end-stage  renal  disease  
FAO Food  and Agriculture  Organization  (of the United  Nations)  
FDA Food  and Drug  Administration  
FSI first subject in 
GCP Good  Clinical  Practice  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 11  
  
 
Abbreviation  Definition  
GGCX  gamma  glutamate  carboxylase  
Gla gamma -carboxyglutamic  acid 
GLP Good  Laboratory  Practice  
HBeAg  hepatitis  B “e” antigen  
HBV hepatitis  B virus 
HCV hepatitis  C virus 
HDL high-density  lipoprotein  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
HIV human  immunodeficiency  virus 
HPLC  high performance  liquid chromatography  
hs-CRP high-sensitivity  C-Reactive  Protein  
ICF informed  consent  form 
ICH International  Conference  on Harmonisation  
ID Identification  
IEC Independent  Ethics  Committee  
IND Investigational  New Drug  application  
INR International  Normalized  Ratio  
IOM Institute of Medicine  
IP investigational  product  
IV intravenous(ly)  
KH2 vitamin K  hydroquinone  
Kt/V measure  of dialysis  adequacy;  K=dialyzer  urea clearance,  t=duration 
of the dialysis session, V=volume of urea distribution  
LC/MS/MS  liquid  chromatography  tandem  mass  spectrometry  
LDL low-density  lipoprotein  
LSLV  last subject  last visit 
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MGP  Matrix  Gla Protein  
MK-[ADDRESS_323668] visit 
PCR polymerase  chain  reaction  
PI[INVESTIGATOR_266018] -II Protein Induced  in Vitamin K Absence/Antagonist -II (also  known as 
descarboxyprothrombin  or des-gamma -carboxy  prothrombin  [DCP])  
PK Pharmacokinetic(s)  
PT preferred  term 
PTT partial  thromboplastin  time 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323669] upper  limit of normal  
[LOCATION_003]/US  United  States of  America  
USP United  States  Pharmacopeia  
VKD vitamin  K-dependent  
VKOR  vitamin K  oxidoreductase  
VKORC1  vitamin  K epoxide  reductase  C1 
VKORC1L1  vitamin  K epoxide  reductase  C1-Like-1 
VKR vitamin  K reductase  
WBC  white  blood cell 
WHO  World  Health  Organization  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 13  
  
 
5. PROTOCOL  SYNOPSIS  
 
Study  Title A Phase  1, Prospective  Safety  Trial of EPN-701 in Subjects  with 
Stable End Stage Renal Disease (ESRD) Receiving Outpatient 
Hemodialysis  
Study  Number  EPN-701-001 
Clinical  Development 
Phase  Phase 1 
Indication  End Stage  Renal  Disease  (ESRD)  on hemodialysis  
Study  Design  This is  a Phase  1, prospective,  open  label  study  to evaluate  the 
safety, tolerability, and pharmacokinetics (PK) of EPN -701, 
administered  once  daily for [ADDRESS_323670]  on a 
stable hemodialysis regimen.  
Study  Objectives  Primary  Objectives:  
• To determine the safety and tolerability of EPN -701 
(administered  for two weeks  at a daily dose  of 10 mg) in 
subjects with ESRD on stable hemodialysis.  
Secondary  Objectives  
• To determine,  in subjects with ESRD on stable hemodialysis, 
the plasma  levels  of the following  biomarkers  after two weeks 
of EPN -701 treatment relative to baseline: uncarboxylated 
MGP; uncarboxylated osteocalcin; Activated Protein C; and 
Protein Induced Vitamin K Absence -II (PI[INVESTIGATOR_266018] -II). 
Exploratory  Objectives:  
• To determine  the pharmacokinetic  profile  of EPN-[ADDRESS_323671] on stable hemodialysis.  
• To determine,  in subjects with ESRD on stable hemodialysis, 
the plasma  levels  of the following  biomarkers  after two weeks 
of EPN -701 treatment relative to baseline: osteoprotegerin, 
Fetuin A, high -sensitivity C -Reactive Protein ( hs-CRP) and 
Time to Formation of Secondary Calciprotein Particles (T -[ADDRESS_323672]), including CPP size.  
Study  Population  A total of [ADDRESS_323673]  meet  all inclusion  criteria  to be enrolled in  the 
study:  
1.  Male or  female ≥18  years  of age 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323674]  missed  (less  than or equal  to) [ADDRESS_323675],  as 
judged by  [CONTACT_266045] (physical examination, medical history, 
clinical laboratory tests, vital signs, and 12 -lead 
electrocardiogram [ECG])  
4. Written  informed  consent  
5. Able and willing  to comply  with the requirements  of the study 
protocol  
6. For females  of child-bearing  potential:  
o Negative  serum  pregnancy  test; 
o Abstinence (refraining from heterosexual intercourse) or 
use of an acceptable contraception for at least [ADDRESS_323676]-menarche, has not reached a postmenopausal state  
( 12 continuous  months  of amenorrhea  with no identified 
cause other than menopause), and has not undergone 
surgical sterilization (removal of ovaries and/or uterus, or 
bilateral tubal ligation).  
Examples of  acceptable contraceptive  methods include: 
hormonal  contraceptives  that inhibit  ovulation,  hormone - 
releasing intrauterine devices, and copper intrauterine 
devices.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 15  
  
 
Exclusion  Criteria  Subjects  meeting  any of the following  exclusion  criteria will  be 
excluded from the study:  
1. Chronic  kidney  disease  not requiring  hemodialysis  
2. Acute  kidney  injury  treated  with hemodialysis  
3. Diagnosis  of confirmed  calciphylaxis  
4. History  of any solid organ  transplant  
5. History of malignancy within 2 years of study enrollment, 
except  for adequately  treated  carcinoma  in situ of the cervix 
and non -melanoma skin carcinoma  
6. History of any major surgery (defined as a surgical procedure 
involving the cranium, chest, abdomen, or pelvic cavity, or 
other  procedure  performed  under  general  anesthesia)  within  [ADDRESS_323677] dose of study drug. Subjects with a 
recent (within <1 month) revision and/or placement of 
arteriovenous fistula (AVF) will be allowed to participate.  
7. History of a major cardiovascular event (such as 
cerebrovascular accident [CVA], transient ischemic attack 
[TIA],  myocardial  infarction,  unstable  angina)  within  [ADDRESS_323678] dose of study drug.  
8. Any co-existing  disease  or condition  that may compromise  the 
safety of study participants and/or the integrity of the study, 
including, but not limited to:  
o Class  C or Class  D Cirrhosis  of the liver 
o Known  intestinal  malabsorption  
o Inability  to take oral medication  
9. Life-expectancy  <3 months  
10. Known history or positive serology for Human 
Immunodeficiency  Virus  (HIV),  positive  serologies  of E antigen 
or with polymerase chain reaction (PCR) positive titers for 
hepatitis B virus (HBV). Subjects with positive serologies for 
hepatitis C but with negative PCR for active virus will be 
allowed.  
11. Severe  infection  requiring  intravenous  (IV) antibiotics  within 
two weeks prior to the first dose of study drug.  
12. Warfarin  taken  within  two weeks  prior to the  first dose  of study 
drug. Subcutaneous heparin, enoxaparin and novel oral 
anticoagulants (NOAC; such as api[INVESTIGATOR_3822]) are permitted.  
13. Treatment  with an investigational  drug within  four weeks  prior 
to the first dose of study drug.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323679] at undue risk by [CONTACT_266046], or cause  inability  to comply  with the trial. 
Study  Assessments  & 
Schedule  A total of 15 consenting subjects meeting the study eligibility 
criteria will  be enrolled and treated with  EPN-701 10  mg (one 10 
mg capsule  to be taken  orally  once  a day, at the same  time each 
morning), for [ADDRESS_323680] - 
treatment safety follow -up. Subjects will undergo a total of 14 
visits during their  study  participation:  Screening  visit (within seven 
days prior to the first dose of study drug), three visits per week 
during the two-week treatment, and two -week safety follow -up 
periods  (coinciding  with the subject’s  hemodialysis  schedule),  and 
the End -of-Study (EOS)/Early Termination visit. Baseline 
assessments will be completed prior to the first study drug intake 
on Day 1. End -of-Treatment (EOT) assessments will be 
completed after the last dose of study drug on study Day 15 (or 
earlier in case of an early discontinuation of the study treatment). 
The EOS/Early Termination visit will occur two weeks after the  
last dose of study dru g (on study Day 29).  
Subjects will be monitored for adverse events (AEs), and 
concomitant medications will  be recorded throughout their study 
participation  (from  screening  through  the EOS/Early  Termination 
Visit). Additional safety assessments will include: physical 
examinations, safety laboratory tests (hematology, including 
complete blood count [CBC]; complete metabolic panel [CMP, 
including electrolytes, renal and liver function tests, and lipid 
profile]; and coagulation panel), vital signs measurements, and 
12-lead ECG. In addition, occurrence of dialyzer clotting will be 
assesse d at each dialysis session, and Kt/V (a measure of 
dialysis  adequacy)  will be calculated  at baseline  (as the average 
of the last three pre -study Kt/V values obtained as part of the 
subject’s standard of care) and at the end of treatment.  
Blood  for PK assessments  will be sampled  as follows:  
• On Day 1 (baseline) and Day 8 (Week 2, on -treatment): pre - 
dialysis  (at the time of needle  placement,  denoted  as 0 hours), 
immediately  followed  by [CONTACT_266047],  and then at 
1 hour (+/- 5 minutes),  2 hours  (+/- 5 minutes),  3 hours  (+/- 5 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 17  
  
 
 minutes),  4 hours  (+/- 30 minutes)/before  needle  removal,  6 
hours  (+/- 30 minutes),  8 hours  (+/- 30 minutes),  and 24 hours 
(+/- 60 minutes) after study drug administration;  
• On Days 3, 5, 10, 12, and 15: pre -dialysis (at the time of 
needle  placement,  at 0 hours),  immediately  followed  by [CONTACT_266048], and then at 4 hours (+/ - 30 
minutes)/before needle removal; and  
• On Day 17 (Week  3, off-treatment)  pre-dialysis  only (at the 
time of needle placement).  
Pre- and post-dialysis  blood  samples  for biomarker  analyses  will 
be collected at Baseline, and on select Mondays during the  
two-week  treatment,  and two-week  safety  follow -up periods.  
Refer  to Table  1, Schedule  of Study  Activities  for further  details.  
Investigational  Medicinal 
Product (IMP; Test 
Product) identity, dose, 
and mode of 
administration  EPN-701 (a new formulation containing highly purified 
Menaquinone -7 or MK -7 as the active ingredient) is the test 
product  in this study,  and will be provided  by [CONTACT_266049]:  
• [ADDRESS_323681] 
identity,  dose,  and mode 
of administration  Not applicable;  this is  an uncontrolled  study.  
Efficacy  Endpoints  Not applicable  
Safety  Endpoints  Primary  Safety  Endpoint:  
• Frequency of treatment -emergent AEs and treatment - 
emergent  AEs assessed  as related  to the study  drug (defined 
as possibly, probably, and definitely related events). A 
treatment -emergent AE is defined as any AE with an onset 
between the first dose of the study drug and the last study 
visit, or any AE with  an onset  prior to first dose  that increases 
in severity or frequency after the first dose of study drug. 
Adverse events include both clinical events and laboratory 
abnormalities that are assessed as clinically significant.  
Secondary  Safety  Endpoints:  
• Frequency of serious adverse events (SAEs), AEs leading to 
study  drug discontinuation,  and AEs of special  interest  (AESI)  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 18  
  
 
 • Changes  from baseline  in safety  laboratory  parameters  
• Changes  from baseline in  vital signs  measurements  
• Changes  from baseline  in ECG  parameters.  
Biomarker  Endpoints  Secondary  Endpoints:  
• Plasma levels of  the following biomarkers  on Day  15 (end -of- 
treatment)  and Day 22 compared  to baseline:  uncarboxylated 
MGP; uncarboxylated osteocalcin; Activated Protein C, and 
PI[INVESTIGATOR_266018] -II protein.  
Exploratory  Endpoints : 
• Plasma levels of the following biomarkers on Day 15 (end -of- 
treatment)  and Day 22 compared  to baseline:  osteoprotegerin, 
Fetuin A, hs-CRP.  
• Time  to Formation  of Secondary  Calciprotein  Particles  (T-[ADDRESS_323682]), including CPP size.  
Pharmacokinetic 
Endpoints  Exploratory  Endpoints:  
• EPN-701 plasma  concentrations  (ng/mL)  at each  measured 
time-point will be determined according to standard 
procedures, using a validated high -performance liquid 
chromatography (HPLC) tandem mass spectrometric 
(LC/MS/MS) method.  
In addition,  depending on the observed plasma  levels,  the 
following  PK parameters  may be determined  for EPN-701: 
• Maximum  plasma  concentration  (Cmax) [ng/mL]  
• Time  to maximum  plasma  concentration  (Tmax) [hr] 
• Area  under  the concentration -time curve  (AUC)  from time 0 to 
24 hours (AUC 0-24 [hr×ng/mL])  
Interim Safety 
Assessments  by [CONTACT_266050] (SRC)  A SRC  will review  the safety  data accumulated  during  the study  at 
regular intervals. The SRC will be comprised of the Sponsor’s 
Medical Monitor, Independent Medical Monitor, and the Principal 
Investigator. Further details will be provided in the SRC Charter.  
Statistical  Methods  Sample  Size Calculation  
No formal  sample  size calculation  was performed.  The selected 
sample size of [ADDRESS_323683] exposure.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 19  
  
 
 Analysis  Populations  
• The safety  population  will include  all subjects  who received  at 
least one dose of study drug.  
• The PK population will  include  all subjects  who received  at 
least one dose of study drug and have sufficient plasma 
concentrations data for PK analysis.  
General  Considerations  
• All analyses will be descriptive. Binary and categorical data 
will be summarized by [CONTACT_11840]. 
Continuous data will be summarized by [CONTACT_3163], standard 
deviations  (SDs),  medians,  and ranges  (minimum,  maximum), 
as appropriate.  
• All data will be included  in appropriate  per-subject  listings.  
Efficacy  Analyses  
Not applicable.  
Safety  Analyses  
• Adverse Events: All AEs will be coded using the current 
version of the Medical Dictionary for Regulatory Activities 
(MedDRA) and will be included in per -subject listings. In 
addition, treatment -emergent AEs will be summarized in 
frequency tables, by [CONTACT_7204] (SOC) 
and by [CONTACT_9560] (PT). Adverse events assessed as 
related to the study drug will be summarized in a similar 
manner.  A summary  of AEs by [CONTACT_266051].  
• Concomitant  Medications:  All concomitant  medications  will be 
coded using the most current version of the World Health 
Organization (WHO) Drug Dictionary and will be included in 
per-subject listings.  
• Laboratory  parameters  will be summarized  at each  time point 
measured using descriptive statistics, including means, SDs, 
medians, and ranges, as appropriate. Change from baseline 
will be summarized similarly, with 95% confidence intervals 
(CIs) for each change. Shift tables may also be provided, if 
warranted by [CONTACT_26739]. All safety laboratory data will be 
included in appropriate per -subject listings, along with 
reference ranges, and indication of clinically significant 
departures from the respective reference ranges.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 20  
  
 
 • ECG  parameters:  will be included  in appropriate  per-subject 
listings and summaries.  
Pharmacokinetic  Analyses  
EPN-701 plasma  concentration  data will be measured  at specific 
timepoints  (see Table  1), tabulated  and summarized.  Descriptive 
statistics for plasma concentrations and PK parameters will 
include arithmetic means and SDs, geometric means and 
coefficients of variation, medians, and ranges, as appropriate.  
Biomarker  Analyses  
Biomarkers will be summarized in a similar manner as described 
for safety  laboratory  parameters,  with summary  at each  time point 
along with change from baseline. Depending of the distribution of 
the biomarkers, transformations to minimize skew and outliers 
may be performed.  
Interim  Analyses  
Not applicable.  
Study  Duration  Overall  Study  Duration:  
All subjects are expected to be enrolled within approximately 
three  months.  The end of  the study  is defined as the last  subject 
last visit (LSLV), which is expected approximately six to seven 
months  after the enrollment  of the first subject.  The actual  length 
of the study and the time for final analysis will depend on the 
recruitment rate.  
Duration  of Study  Participation  Per Subject:  
The expected duration of the study for an individual subject is 
approximately  five weeks,  including  up to one week  for screening, 
two weeks of study treatment, and two weeks of post -treatment 
safety follow -up. Subjects will undergo a total of 14 visits during 
the study participation.  
Participating  Centers  The study  will be conducted  at one to three  dialysis  centers  in the 
[LOCATION_002].  
The schedule  of study  activities  is provided  in Table  1 below.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323684] -TREATMENT  EOS/ 
EARLY 
TERMINA 
TION  VISIT  SCHEDULE  Screening  1 
BL 2 3 4 5 6 7 
EOT 8 9 10 11 12 
Study  Day -7 to -1 1 3 5 8 10 12 15 17 19 22 24 26 29 
Day of the week   Mon Wed Fri Mon Wed Fri Mon Wed Fri Mon Wed Fri Mon 
Informed  Consent  & HIPAA  Authorization  X              
Demographics  [1] X              
Medical  History  [2] X              
Disease  History  [3] X              
Physical  examination  [4] X       (X)      X 
Weight  and height  measurements  [5] X X X X X X X X      X 
Standard  12-lead ECG  [6] X       X      X 
Vital signs  measurements  [7] X X X X X X X X      X 
Hematology,  CMP,  Coagulation  panel  [8] X X   X   X   X   X 
Testing  for HIV, Hepatitis  B and C [9] X              
Serum  β-hCG Pregnancy  Test [10] X              
Eligibility  Criteria  X X             
Concomitant  Medications  [11] X X X X X X X X X X X X X X 
Adverse  Event  recording  [12]  X X X X X X X X X X X X X 
Study  drug administration  [13]  Once  daily,  from Day 1 through Day  14        
EPN-701 PK assessments  [14]  X X X X X X X X      
Kt/V assessment  [15]  X      X       
Biomarker  assessments  
MGP,  Osteocalcin,  Activated  Protein  C, 
PI[INVESTIGATOR_266018] -II protein, Fetuin A,  
osteoprotegerin,  hs-CRP,  and Time  to 
Formation of Secondary Calciprotein    
X       
X    
X    
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323685] -TREATMENT  EOS/ 
EARLY 
TERMINA 
TION  VISIT  SCHEDULE  Screening  1 
BL 2 3 4 5 6 7 
EOT 8 9 10 11 12 
Study  Day -7 to -1 1 3 5 8 10 12 15 17 19 22 24 26 29 
Day of the week   Mon Wed Fri Mon Wed Fri Mon Wed Fri Mon Wed Fri Mon 
Particles  (T-[ADDRESS_323686]),  including  CPP size 
[16]               
Abbreviations: AE=adverse event; AESI=adverse event of special interest; ALT=alanine amino transferase; AST=aspartate amino transferase; 
BL=Baseline (visit); BUN=blood urea nitrogen; CMP=Complete Metabolic Panel; CPP=calciprotein particles; DNA=deoxyribonucleic acid; 
ECG=electrocardiogram;  EOS=End -of-Study  (visit);  EOT=End -of-Treatment  (visit);  β-hCG=beta -human  chorionic  gonadotropin  (pregnancy  test); 
HDL=high -density lipoprotein; hs-CRP=high sensitivity C -reactive protein; INR=international normalized ratio; K=dialyzer clearance; 
LC/MS/MS=liquid chromatography tandem mass spectrometry; LDL=low -density lipoprotein; MGP=Matrix Gla protein; PK=pharmacokinetic(s); 
PTT=partial thromboplastin time; RBC=red blood cell (count); RNA=  ribonucleic acid; SAE=serious adverse event; t=time; T -[ADDRESS_323687]=Time to 
Formation of Secondary Calciprotein Particles; V=volume of urea distribution; WBC=white blood cell (count)  
Note:  Visit 1 will be  the Baseline  visit. End-of-Treatment  (EOT)  assessments  will be  completed  after the last dose  of study  drug on study  Day 
15/Visit 7 (or earlier in case of an early discontinuation of the study treatment).  
[1] Demographic  data include  age, sex, and self-reported  race/ethnicity.  
[2] General medical  history  includes  clinically  significant  diseases  (except  those  listed under  “Disease history”),  surgeries,  reproductive status,  and 
any conditions/symptoms present prior to the first dose of study drug.  
[3] Disease  history  includes  details  on the underlying  condition,  including  renal  (ESRD)  and dialysis  history.  
[4] A complete  physical examination  will be  performed  at screening  and at the EOS  visit on Day 29. A symptom -driven  (abbreviated)  physical 
examination may be performed at the EOT visit (Day 15), if the investigator deems it clinically indicated.  
[5] Subjects will undergo body weight  and height measurement at screening/baseline, and  body weight measurements (as part of their  standard 
care on dialysis  days)  within  [ADDRESS_323688]-dialysis  on each  dialysis  day during  the 2-week  treatment  period 
(Visits 1 through 6), at the EOT visit (Day 15), and EOS visit (Day 29).  
[6] Standard  12-lead ECG  recordings  will be  obtained  within  60 minutes  pre-dialysis  at screening/baseline,  at EOT (Day  15), and at EOS  (Day 29). 
ECG recordings should be performed after the subject has been resting in a supi[INVESTIGATOR_21683] 5 minutes, and prior to other procedures 
scheduled at that same time (e.g., blood draws).  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 23  
 [7] Vital signs (including blood pressure, heart rate, respi[INVESTIGATOR_697], and oral body temperature) will be measured at screening, and (as part of 
their standard  care on dialysis  days)  within  [ADDRESS_323689]-dialysis  at each  treatment  visit (Visits  1 through  6), 
at EOT (Day 15), and EOS (Day 29).  
[8] All blood sampling will occur  pre-dialysis (at the time of needle placement) . Hematology  panel includes:  RBC count, hemoglobin, hematocrit, 
and WBC count with differential (neutrophils,  eosinophils, lymphocytes, monocytes, basophils, and other cells), if clinically indicated. CMP 
includes:  glucose,  albumin,  total protein,  electrolytes  (sodium,  potassium,  bicarbonate,  chloride,  calcium, magnesium,  phosphate),  renal function 
tests (BUN, creatinine), liver function tests (ALT, AST, bilirubin), and lipid profile (total cholesterol, LDL cholesterol, H DL cholesterol, and 
triglycerides). Coagulation panel includes: PTT, INR, and platelet count.  
[9] Serology  for: HIV, HBV (hepatitis  B “e” antigen [HBeAg]  and PCR  for the active virus  [HBV  DNA]);  and HCV (HCV  antibody  and PCR  for active 
virus [HCV RNA])  
 
 
[10] Women of  child bearing  potential must  undergo a  serum  β-hCG pregnancy  test within [ADDRESS_323690] be negative for enrollment.  
[11] All medications  (including over -the-counter medications)  or therapy administered to  the subject during the  [ADDRESS_323691] dose of 
study  drug will be recorded  at screening/baseline.  Any changes  to concomitant  medications  will be  documented  regularly  throughout  the study.  
[12] All AEs with an onset between the time the informed consent  is signed and [ADDRESS_323692]  dose of study drug (EOS/Early  Termination 
visit) are to  be recorded on the appropriate Adverse Event CRF  pages  and in source documents. SAEs, AESIs, and pregnancies  occurring during 
or within [ADDRESS_323693] dose of EPN -701 will also be reported in an expedited fashion. SAEs and AESI considered to be related to the 
study  drug by  [CONTACT_093],  will be  reported  to the Sponsor even  if they occurred after the  protocol -specified  reporting period  (i.e., more than [ADDRESS_323694] dose of EPN -701). Any occurrence of dialyzer clotting (assessed at each dialysis session) is to be recorded as an AE.  
[13] EPN-701 10 mg per day (1 capsule  of 10 mg). The study  drug will be taken  at approximately  the same  time each  morning.  On hemodialysis 
days (Days 1, 3, 5, 8, 10, and 12), subjects will take their study drug dose pre -dialysis (immediately after needle placement and biomarker 
sampling, as applicable); on the remaining days during  Weeks 1 and 2, subjects will take their study drug dose at home.  
[14] Blood  for PK assessments will  be sampled  as follows:  
• On Day 1 (baseline) and Day 8 (Week 2, on-treatment): pre -dialysis (at the time of needle placement, denoted as 0 hours), immediately 
followed by [CONTACT_266052], and then at 1 hour (+/ - 5 minutes), 2 hours (+/ - 5 minutes), 3 hours (+/ - 5 minutes), 4 hours (+/ - 30 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 24  
 minutes)/before  needle  removal,  6 hours  (+/- 30 minutes),  8 hours  (+/- 30 minutes),  and 24 hours  (+/- 60 minutes)  after study  drug 
administration;  
• On Days  3, 5, 10, 12, and 15: pre-dialysis  (at the time of  needle placement,  at 0 hours),  immediately  followed by  [CONTACT_266047], 
and then at 4 hours (+/ - 30 minutes)/before needle removal; and  
• On Day 17 (Week 3, off -treatment): pre -dialysis only (at the time of needle placement). 
Plasma  levels  of EPN-701 will be  determined  using  a validated  high-performance  LC/MS/MS  method.  
[15] Kt/V (a standard  measure of dialysis adequacy) will be calculated at  baseline  (as the average of the  last three pre -study Kt/V values  obtained 
as part of the subject’s standard of care), and at EOT (Day 15). In case the Kt/V value obtained at EOT is  reduced compared to baseline (pre - 
study  measurements),  the Investigator  will determine  (in consultation  with the Medical Monitor,  as needed)  if the event  qualifies  for reporting  as an 
AE. 
[16] Blood  sampling  will always  occur  pre-dialysis  (at the time of needle  placement):  on Day 1 (Baseline),  Day 15 (EOT),  and Day 22 ([ADDRESS_323695] study drug dose), for a total of 3 samples collected. Plasma levels of the following biomarkers will be assessed: un carboxylated MGP; 
uncarboxylated osteocalcin, Activated Protein C, PI[INVESTIGATOR_266018] -II protein, Fetuin A, osteoprotegerin, hs-CRP, and Time to Formation of Secondary 
Calciprotein Particles (T -[ADDRESS_323696]), including CPP size. Instructions for specimen collection and handling will be included in the laboratory manual 
provided by [CONTACT_15622].  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 25  
  
6. BACKGROUND  
 
The current Phase 1 clinical trial is a prospective safety study of EPN -701 in subjects currently 
receiving  stable  hemodialysis  for end-stage  renal  disease  (ESRD).  EPN-701 is a new formulation 
containing highly purified MK -7. MK -7 belongs to a family of compounds called menaquinones, 
collectively known as vitamin K2. EPN -701 is being developed for the treatment  of calciphylaxis 
(also  referred  to as Calcific  Uremic  Arteriolopathy  [CUA]),  a rare, but potentially  fatal complication 
of chronic kidney disease (CKD), predominantly affecting patients with ESRD on dialysis. The 
condition is characterized by [CONTACT_266053] (Janigan 2000 ; Brandenburg et al. 2016 ; Brandenburg et al. 2017 ). 
While  the mechanisms  for soft tissue  calcification  are not fully understood;  there  is a growing  body 
of evidence  that the uremic  condition  of both CKD  and ESRD  patients  contributes  to a functional 
deficiency  of vitamin  K. Subject  to approval  by [CONTACT_1622],  EPN-[ADDRESS_323697] and only drug 
approved for the orphan indication calciphylaxis (CUA) to address peripheral soft tissue 
calcification  and medial  calcification  of the smooth  muscle  cells of the  vasculature.  The following 
section  provides  an overview  of (i) the impact  of ESRD  and hemodialysis  on the vitamin  K cycle;  
(ii) long -acting derivatives of vitamin K2; non -clinical and clinical background on EPN -701, and 
rationale for the current study, including key study design elements.  
 
6.[ADDRESS_323698] of Hemodialysis  
 
Vitamin K is an essential enzymatic co -factor that is required for posttranslational modifications 
of vitamin K-dependent (VKD) proteins. Of the numerous VKD proteins, several are clinically 
relevant  to ESRD  patients.  They  include  the central  coagulation  factors  such  as factors  II, VII, IX, 
and X, as well as intercellular  matrix  proteins  including  matrix  gamma -carboxyglutamic  acid (Gla) 
protein  (MGP)  and osteocalcin  (also  referred  to as bone  Gla protein  [BGP]).  It has been  proposed 
that vitamin  K is reduced  to vitamin  K hydroquinone  (KH2)  via two pathways:  a warfarin -sensitive 
pathway (by [CONTACT_1996] K epoxide reductase [VKORC1]) and a warfarin -resistant pathway (Tie and  
Stafford,  2016 ). It is only the reduced  form of vitamin  K that can function  as a co-factor  for gamma 
glutamate carboxylase (GGCX) which catalyzes the carboxylation of VKD proteins (Gallieni  and 
Fusaro,  2014 ). Warfarin  blocks  the generation  of vitamin  K hydroquinone  by [CONTACT_266054] K recycling ( Figure 1 ). The enzymatic carboxylation of  glutamate residues results 
in further  oxidation  of vitamin  KH2 to 2,3-epoxide  Vitamin  K. The  final step of the  vitamin  K cycle 
requires the enzymatic reduction of vitamin K 2,3 -epoxide back to its native structure. This step 
is catalyzed  by [CONTACT_266055]1  and is a component  of the vitamin  K cycle  along  with warfarin  (Figure  1) 
(Gallieni and Fusaro, 2014 ). 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 26  
 
Figure  1 – Vitamin  K Cycle  
 
Conversion  of glutamate  (Glu)  to g-carboxyglutamate  (Gla)  residues  by g-glutamyl  carboxylase  (GGCX)  (1) is essential 
for the activation of vitamin K -dependent (VKD) proteins. g -Carboxylation  transforms undercarboxylated (ucVKD) into 
carboxylated (cVKD) proteins. Vitamin K hydroquinone (KH2) is oxidized to vitamin K epoxide (KO). KO is converted 
to vitamin K quinone by [CONTACT_1996] K epoxide reductase (2). A similar reductase enzymatic reaction (2) converts vitamin 
K quinone  back into KH2.  Another  reductase,  NAD(P)H -dependent  vitamin  K reductase  (3), or DT-diaphorase,  can also 
catalyze the  same  conversion  into KH2.  Warfarin inhibits  the reductase activity  (2) that is dithiol  dependent but  not the 
NADPH -dependent reductase (3), whose substrate can be dietary vitamin K.  
Source:  Gallieni  and Fusaro, [ADDRESS_323699] isoenzymes (VKORC1 and VKORC1 - 
Like-1 [VKORC1L1]) that differ in both enzymatic properties and tissue distribution (Tie et al.  
2011 ). VKORC1  and VKORC1L1  both catalyze  the reduction  of 2,3-epoxide  vitamin  K via vitamin 
K quinone  to vitamin  K hydroquinone.  VKORC1  is the key enzyme  of the classical  vitamin  K cycle 
by [CONTACT_266056] γ-carboxylated  by [CONTACT_266057].  In contrast,  the VKORC1  paralog 
enzyme,  VKORC1L1,  is mainly  responsible  for antioxidative  function  by [CONTACT_266058]  K to 
prevent damage by [CONTACT_266059] (ROS) (Caspers et al. 2015 ). The 
available data also suggest that there is an as -yet-unidentified vitamin K reductase (VKR) 
(different  from VKORC1)  in the vitamin  K-dependent  carboxylation  that allows  warfarin  poisoning 
to be overcome (Tie and Stafford, 2016 ). 
Westhofen et al have shown that compared to VKORC1, VKORC1L1 has a 3 -fold lower affinity 
for 2,3 -epoxide vitamin K (Westhofen et al. 2011 ). Subsequent work supported the hypothesis 
that VKORC1L1 is a specialized isoform that protects against oxidant injury through the 
regeneration  of vitamin  K. When  cultured  HEK293T  cells were incubated  with hydrogen  peroxide  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 27  
 (H2O2), VKORC1L1 expression was increased and evidence of membrane oxidant injury was 
reduced (Westhofen et al. 2011 ; Tie et al. 2013 ). Cumulatively, observations reported to date 
suggest that any condition or procedure (i.e. hemodialysis) that blocks re -constitution of vitamin 
K predisposes that tissue to pathologic calcification (Caspers et al. 2015 ). 
It is widely recognized that despi[INVESTIGATOR_266020], vitamin K levels among ESRD patients 
may not be reduced.  For example,  Holder  et.al studied  172 stable  dialysis  patients  and found  that 
only 6% of patients exhibited a clinically significant deficiency in vitamin K. However, when 
patients  were  examined  for the level of uncarboxylated  osteocalcin,  60% of patients  had reduced 
levels  (Holden  et al. 2010 ). To confirm  that this was a general  effect  of reduced  vitamin  K activity, 
the authors also measured PI[INVESTIGATOR_266018] -II; another  vitamin K -dependent protein. Indeed, 90% of both 
CKD  and ESRD  patients  were  found  to have  reduced  levels  of carboxylated  prothrombin  (Holden  
et al. 2010 ). In a similar  study, Pi[INVESTIGATOR_266021] K1 levels in [ADDRESS_323700] patients had adequate vitamin K stores but 93% of patients had 
uncarboxylated osteocalcin levels that were greater than 20% of the total osteocalcin levels, 
consistent with a subclinical  vitamin K deficiency  (Pi[INVESTIGATOR_266022]. 2007 ). It is interesting to note that 
there was no correlation between total  vitamin K1 and the levels of  circulating of  uncarboxylated 
osteocalcin.  This unexpected  finding  is consistent  with the hypothesis  that in uremic  patients,  total 
vitamin K levels can be normal while generation of reduced forms are blocked by [CONTACT_266060] (Stockler -Pi[INVESTIGATOR_266023]. 2016 ). 
Evidence  in the literature  suggests  that insufficient  availability  of menaquinones  is associated  with 
higher levels of dephosphorylated and uncarboxylated MGP (dp -ucMGP), and there is a 
significant  correlation  between  dp-ucMGP  and presence  of soft tissue  calcification (Schurgers  et 
al., 2010 ; Delanaye et al. 2014 ). These observations suggest that some aspect of the uremic 
condition or even the process of dialysis neutralizes the carboxylating effects of vitamin K. 
Pi[INVESTIGATOR_266024]. and others have confirmed that the simple delivery of 
hemodialysis  can lead to the oxidation  of numerous  tissue  proteins  (Himmelfarb  et al. 2000 ), such 
as the oxidation of the hydroxyl amino acid side chains to carbonyl groups (see Figure 2 ). 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 28  
 
Figure  2 – The Oxidation  of Protein  Residues  Serine  and Threonine  
Serine  O 
Residue  O 
 
N 
H 
 
 
 
 
Threonine 
Residue  
 
N 
H OH N O H 
HN Uremia  Induced  HN 
Oxidation  
 
 
O OH O O 
 
 
N 
H 
HN HN 
 
In a study  of CKD  and ESRD  patients,  using  carbonyl  side chain  oxidation  as a measure  of global 
oxidant  burden,  Himmelfarb  et al demonstrated  that both CKD  and ESRD  patients  exhibit  a higher 
percentage (15 -fold) of carbonyl proteins compared to normal controls (see Figure 3 ). The 
percentage of carbonyl proteins was even higher among patients receiving dialysis, 
demonstrating  that not only does  dialysis  not reduce  oxidative  burden,  it appears  to contribute  to 
it (Himmelfarb et al. 2000 ). We propose that the oxidative load generated by [CONTACT_266061]2 to the non -functional native vitamin. The 
oxidation  of KH2 by [CONTACT_266062] a co-factor  for GGCX,  which 
downstream leads to reduced gamma carboxylation of vitamin K -dependent proteins.  
 
Figure  3 – In vivo Plasma  Protein  Carbonyl  Formation  
 
*P=0.05  vs. normal  volunteers  (N=10  in each  group). Error  bars represent  standard  error of the mean.  
Source: Himmelfarb  et al. 2000 

EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 29  
 
6.1.2  Long -Active  Derivatives  of Vitamin  K2: Therapeutic  role for 
Menaquinone -7 
 
EPN-701 is a new formulation containing highly purified menaquinone -7 (MK -7) that belongs to 
the vitamin  K2 family  of compounds.  Subject  to approval  by [CONTACT_1622],  EPN-[ADDRESS_323701] 
and only drug approved  for the orphan  indication  Calciphylaxis  (also  referred  to as Calcific  Uremic 
Arteriolopathy [CUA]), specifically to address peripheral soft tissue calcification and related 
calcification  of the medial  smooth  muscle  cells of the vasculature  present  in most  ESRD  patients. 
Menaquinones have a common functional naphthoquinone ring system (also shared with 
phylloquinone) and an unsaturated polyisoprenyl side chain. They are designated based on the 
length of the aliphatic side chains attached to the naphthoquinone ring (Booth and Suttie, 1998 ; 
Shearer  and Newman,  2008 ). Menaquinone  nomenclature  is based  on the number  of isoprenoid 
units, and ranges from 1 to 15 (e.g., MK -7 for the vitamer with a side chain consisting of 7 
isoprenoid units) (Marles et al. 2017 ). The chemical structure of MK -4 and MK -7 compared to 
phylloquinone (vitamin K1) is presented in Figure [ADDRESS_323702],  MK-4 has 
a half -life of approximately 3 hours (Schurgers and Vermeer, 2002 ; Schurgers et al. 2007c ). 
Dietary sources of menaquinones include chicken, egg yolk, dairy products, cow liver, and 
fermented  foods  such  as cheese,  yogurt,  sauerkraut,  and natto,  a traditional  Japanese  food made 
from soybeans fermented with Bacillus subtilis varnatto (Schurgers et al. 2007c ; Marles et al.  
2017 ). 
 
Figure  4 – Vitamin  K Structures  
 
The naphthoquinone  ring system  shared  by [CONTACT_266063] (vitamin  K1) and menaquinones MK -4 and MK-7 (vitamin 
K2). The designation of MK -4 versus MK -7 is dependent upon the length of the aliphatic side chains attached to the 
naphthoquinone ring.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323703] a manufacturer’s suggested MK -7 
dose of 50 μg/d (NIH DSLD 2016 ). The Acceptable Daily Intake is 120 μg/day (FDA 2012 ). 
 
6.2 BACKGROUND  ON EPN-701 
 
EPN-701 is a new formulation  containing  highly  purified  MK-7. MK-7 belongs  to a family  of 
compounds called menaquinones, collectively known as vitamin K2.  
The following sections provide an overview of non -clinical  and clinical  data on MK -7. For further 
details, refer to the EPN -701 Investigator's Brochure.  
6.2.1  Summary  of Nonclinical Studies  
 
The active ingredient  in EPN -701 (MK -7) has been studied extensively in a variety of  nonclinical 
animal models.  
In a rat model  of cardiovascular  calcification,  MK-[ADDRESS_323704] on secondary 
mineralization of damaged  vascular structures and not to a reduction in vascular damage.  MK-7 
supplementation  also inhibited  the increase  in aortic  alkaline  phosphatase  activity  and resulted  in 
a 10-fold increase  in the expression  of the MGP  messenger  ribonucleic  acid (mRNA)  in the aorta 
(Scheiber et al. 2015 ). Given that MGP is a potent inhibitor of arterial calcification, EPN -701 
administration could be a beneficial treatment for calciphylaxis patients.  
Published  non-clinical  toxicology  studies  of MK-7 include  single -dose  toxicity  studies  in mice  and 
rats, and two -week, five -week, and two 13 -week repeat -dose toxicity studies in rats. 
Administration of single oral doses of MK -7 at 2000 mg/kg (equivalent to a human dose of 9730 
mg) to five female mice was not associated with signs of toxicity during the 14 -day observation 
period (Pucaj et al. 2011 ). There were no signs of toxicity, effects on body weight (growth), or 
gross pathologic findings at necropsy after administration of 0.5, 1,10, 20, 2000 mg/kg/day 
(equivalent  to human  doses  of 5, 10, 97, 194, [ZIP_CODE]  mg/day,  respectively)  to eight  rats (four male, 
four female)  for 14 days  (Ravishankar  et al. 2015 ). In a Good  Laboratory  Practice  (GLP) -compliant 
study with [ADDRESS_323705] -level (NOAEL) was 
determined  to be 10 mg/day,  the highest  dose  tested  (Pucaj  et al. 2011 ), which is  equivalent  to a 
dose level of 97 mg/day in a [ADDRESS_323706]. The five -week NOAEL for effects on 
cardiovascular function was also 10  mg/kg/day (97 mg/day in a [ADDRESS_323707]), the only 
dose  level tested  (Siltari  et al. 2014 ). These  studies  support  the 10 mg/day  dose  in the EPN-701- 
[ADDRESS_323708] shown that MK -7 has no mutagenic or clastogenic potential 
(Ravishankar et al. 2015 ). 
Refer  to the EPN-701 Investigator’s  Brochure  for further  details  on the nonclinical  studies.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323709] clinical  investigation  of EPN-701 in humans.  Data 
on the clinical  benefits and safety of MK -7 (the active ingredient in EPN -701) are available from 
numerous clinical trials and are briefly summarized below.  
[IP_ADDRESS]  Summary  of the  Clinical Benefits  of MK-7 
 
The active ingredient in EPN -701 (MK -7) has been studied extensively in humans. Published 
reports of clinical trials conducted with MK -[ADDRESS_323710] of MK -7 on various disease indications.  
High dietary menaquinone intake was associated with several beneficial effects in clinical trials 
involving more than 57,000 women and men, including: (1) Reduced coronary calcification in a 
cohort  of [ADDRESS_323711] -menopausal  women (Beulens et  al. 2009 ); (2) Reduced risk of  coronary  heart 
disease (CHD) in 16,057 women aged 49 -70 years (Gast et al. 2008 ); (3) Reduced relative risk 
(RR)  of CHD  mortality,  all-cause  mortality  and severe  aortic  calcification  in 4807  subjects  with no 
history of myocardial infarction at baseline (Geleijnse et al. 2004 ); (4) No increase in the risk of 
stroke (hemorrhagic, ischemic, or overall) in a prospective cohort of 35,476 Dutch men and 
women (average age of 49 years, 74% women) during a follow -up of approximately 12 years 
(Vissers et al. 2013 ); (5) In addition, results of one study involving 105 women suggested that 
higher  MK-7 level resulting  from natto  consumption  may contribute  to the relatively  lower  fracture 
risk in Japanese women (Kaneki et al. 2001 ). 
Long -term use of MK -7 supplements (180 µg/day for 3 years) improved arterial stiffness in 244 
healthy postmenopausal women enrolled in a double -blind, randomized, placebo -controlled trial 
(Knapen et al. 2015 ). 
In a prospective cohort analysis of 7216 participants at high cardiovascular disease risk, 
individuals who increased their intake of vitamin K1 or K2 during the follow -up period (median, 
4.8 years) had a significantly lower risk of cancer and all -cause mortality, and no increase in 
cardiovascular mortality compared to those who decreased or did not change their intake 
(Juanola -Falgarona et al. 2010 ). 
[IP_ADDRESS]  Summary  of the Clinical Safety  of MK-[ADDRESS_323712] been 
performed  in humans  with MK-7 at various  doses  and frequencies,  both in healthy  volunteers  and 
patients with various diseases. Several published clinical trials evaluated the safety of MK -7. 
Cumulatively,  the findings  from these  studies indicate,  that treatment  with MK -7 at levels  of up to 
180 μg/day  for 3 years  (Knapen  et al. 2013 ; Knapen  et al. 2015 ), or up to 360 μg/day  for 12 weeks 
(Theuwissen  et al. 2012 ; Dalmeijer  et al. 2012 ), or of up to 1080  μg three  times  weekly  for 8 weeks 
(Caluwé et al. 2014 ) in treatment populations of up to [ADDRESS_323713]’s smell (Marles et al. 2017 ). 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 32  
 Similarly, a systematic review and meta -analysis of 13 randomized controlled trials (N=1366) 
evaluating vitamin K1 and K2 supplementation for the prevention of bone fractures, none of the 
included studies reporting any serious adverse events (SAEs) associated with vitamin K 
(Cockayne et al. 2006 ). 
A comprehensive  review  of the available  evidence  supporting  the safety  of MK-7 as an ingredient 
of dietary supplements was recently published (Marles et al. 2017 ). A search of the literature by 
[CONTACT_120845] (IOM) revealed no evidence of toxicity associated with the natural 
menaquinones.  Given  the lack of adverse  effects  in humans  or animals  consuming  high doses  of 
vitamin K, the IOM was unable to derive a Tolerable Upper Intake Level  (IOM 2001 ). The World 
Health Organization (WHO)  and Food and Agriculture Organization (FAO)  of the United Nations 
(WHO/FAO  2004 ) concluded  that oral natural  K vitamins  seem to  be free of toxic side effects,  an 
observation based on clinical administration of doses of 10 -20 mg/day or more. The European 
Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies conducted a 
safety  assessment  of vitamin K2 (principally MK -7) added to food for  nutritional  purposes (EFSA  
2008 ) and concluded  there  were  no adverse  effects  of MK-7 on blood  coagulation  at doses  of up 
to 6 μg/kg/day in adults and 1.5 μg/kg/day in children.  
Overall,  the conclusions  of the reviews  by [CONTACT_266064] a favorable  benefit 
to risk ratio for vitamin K2 (Marles et al. 2017 ). 
6.2.[ADDRESS_323714] investigation  of the pharmacokinetics  (PK) of EPN- 
[ADDRESS_323715] a 
much  longer  half-life than vitamin  K1 (68 hours  vs 1-2 hours).  Both MK-[ADDRESS_323716] treatment, from 0 to 500 μg; however, at [ADDRESS_323717] an upper limit of normal range for total serum vitamin K (1  μg/L), whereas 
there was no effect of vitamin K1 at up to [ADDRESS_323718] two weeks 
until it reached a plateau level of approximately 6 μg/L (Schurgers et al. 2007c ). 
6.2.4  Anticipated  Risks  Associated  with EPN-701 
 
As detailed in Section [IP_ADDRESS] , several published clinical trials evaluated the safety of MK -7. 
Cumulatively,  the findings  from these  studies  indicate,  that treatment  with MK -7 at individual  daily 
doses of up to 1080 μg three times per week (Caluwé et al. 2014 ) was not associated with 
significant  adverse  effects  compared  with placebo.  Adverse  effects  specifically  attributed  to 
MK-[ADDRESS_323719]’s  smell  (Marles  et al. 2017) . 
There  is a risk for interaction  between  EPN-701 and anticoagulant  drugs  (Marles  et al. 2017 ). 
Additional details are provided in the EPN -701 Investigator’s Brochure.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323720] 
on hemodialysis, despi[INVESTIGATOR_266025] (10  mg/day) 
compared to the daily doses administered in clinical trials of MK -7 supplementation (up to 1080 
μg three times per week). Nevertheless, appropriate measures will be implemented to evaluate 
and minimize the potential risks related EPN -701 throughout the study. These will include 
continuous adverse event monitoring, and regular clinical and laboratory safety assessments. A 
Safety Review Committee (SRC) will review the safety data accumulated during the study at 
regular intervals. The SRC will be comprised of the Sponsor’s Medical Monitor, Independent 
Medical Monitor, and the Principal Investigator. Further details will be provided in the SRC 
Charter.  
 
6.[ADDRESS_323721]  developed  calciphylaxis will  be excluded from 
the current study.  
The primary  objective  of the EPN-701-001 study  is to determine  the safety  and tolerability  of EPN- 
701 (administered for two weeks at a daily dose of 10 mg) in subjects with ESRD on chronic 
stable hemodialysis.  
Once the safety  and tolerability of the 10 mg dose is determined in the current  Phase 1 study, a 
Phase  2b clinical  trial is planned  to determine  whether  EPN-701 can normalize levels  of calcium - 
chelating proteins and subsequently accelerate the rate of healing of calciphylaxis lesions.  
6.3.2  Rationale  for the EPN-701 Dose  and Schedule  
 
In a GLP -compliant  study  evaluating 13 -week repeat  dosing in rats,  the NOAEL was determined 
to be 10  mg/kg/day, the highest dose tested (Pucaj et al. 2011 ), which is equivalent  to a dose of 
approximately 97 mg/day in a [ADDRESS_323722]. Additionally, a two -week repeat dose study 
in rats included dosing MK -7 as high as 2000 mg/kg/day and resulted in no signs of toxicity 
(Ravishankar  et al. 2015 ). This equates  to a human  equivalent  dose  of approximately  19.4 g/day.  
There  is no known  published  LD-50 level for menaquinone -7. 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 34  
 The dose selected for the current clinical study is 10 mg/day, providing a 10 -fold safety margin 
over the established NOAEL in rats. Therefore, the available data on MK -7 provide sufficient 
evidence of safety to support the proposed clinical study evaluating EPN -701 in humans.  
In addition, the existing literature (Westenfeld et al. 2012 ; Caluwe et al. 2014 ) indicates that 
administration  of 1.0 mg of MK-7 resulted  in an approximately  50% absolute  reduction/conversion 
of uncarboxylated matrix GLA protein to carboxylated matrix GLA protein, which is the only 
functional form of the protein capable of inhibiting the deposition of calcium in soft tissues. 
Therefore,  a [ADDRESS_323723]  functional,  but modifiable,  vitamin 
K deficiency (Cranenburg et al. 2012 ; Elliott et al. 2014 ), and multiple biomarkers have been 
tested  as measures  of vitamin  K status  in these  patients  (Elliott  et al. 2014 ). PI[INVESTIGATOR_266018] -II is a measure 
of prothrombin  undercarboxylation,  with elevated  levels  corresponding  to poorer  vitamin  K status. 
As a biomarker of vitamin K status, PI[INVESTIGATOR_266018] -II has the advantage of being independent of kidney 
function and lipid profile (Elliott et al. 2014 ). 
MGP is a potent calcification inhibitor of the arterial wall and other soft tissues, and its activity 
depends  on vitamin  K-dependent  γ-glutamate  carboxylation  (Schurgers  et al. 2007a ; Westenfeld  
et al. 2012 ; Schurgers et al. 2013 ; Marles et al. 2017 ). Uncarboxylated MGP, formed as a result 
of vitamin K deficiency, is associated with cardiovascular disease. Recent studies suggest poor 
vitamin K status in hemodialysis patients (Westenfeld et al. 2012 ). The circulating inactive form 
of MGP  (dp-ucMGP)  was shown  to increase  progressively  in patients  with CKD  (Schurgers  et al. 
2010 ) and to be predictive  of vitamin  K status  and correlated  with vascular  calcification  in patients 
on hemodialysis (Delanaye et al. 2014 ). Plasma dp -ucMGP has therefore been proposed as a 
surrogate  marker  for vascular  calcification  in CKD  (Schurgers  et al. 2010 ). In addition,  lower  levels 
of circulating  desphospho -carboxylated  MGP  (dp-cMGP)  was proposed  as a predictor  of mortality 
in dialysis patients (Schlieper et al. 2011 ). 
Osteocalcin is a non -collagenous bone matrix protein synthesized by [CONTACT_266065], and 
involved in bone formation and regulation of  bone  mineralization (Elliott  et al. 2014 ; Marles et  al. 
2017 ). The proportion of osteocalcin that is uncarboxylated is a sensitive marker of vitamin  K 
status  in bone,  and subclinical  vitamin  K deficiency  is defined  by [CONTACT_266066]  20% (Elliott  et al. 2014 ). Supplementation  with MK -7 at doses 
of 100 –200 mg/d for 4 to 12 weeks was shown to increase the ratio of carboxylated to 
undercarboxylated  osteocalcin  significantly  and in a dose -dependent  manner  (Inaba  et al. 2015 ). 
Vitamin  K-dependent  γ-carboxyglutamate  proteins  are synthesized  in the liver,  and help maintain 
normal blood coagulation through a balance of both procoagulant factors (II, VII, IX, and X) and 
anticoagulant proteins (C and S) (Schurgers et al. 2007c ; Marles et al. 2017 ). Activated Protein 
C regulates the coagulation process by [CONTACT_266067] V and 
VIII in the presence  of the cofactor  Protein  S (Marlar  and Gausman,  2017 ). Hypercoagulable  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 35  
 states, such as protein C and/or protein S deficiencies have been reported in patients with 
calciphylaxis  (the ultimate  target  population  for EPN-701),  and proposed  as factors  increasing  the 
likelihood of calciphylaxis development (Wilmer and Magro, 2002 ; Nigwekar et al. 2008 ). 
In a randomized study evaluating the effect of  vitamin K2 supplementation on functional  vitamin 
K deficiency in adult hemodialysis patients, patients on hemodialysis (N=53) had 4.5 -fold higher 
dp-ucMGP and 8.4 -fold higher uncarboxylated osteocalcin levels compared with healthy age - 
matched  controls (N=50).  PI[INVESTIGATOR_266018] -II levels were elevated in 49 hemodialysis patients.  Vitamin K2 
supplementation induced a dose - and time -dependent decrease in circulating dp -ucMGP, 
uncarboxylated osteocalcin, and PI[INVESTIGATOR_266018] -II levels. Response rates in the reduction in dp -ucMGP 
levels were 77% and 93% in the groups receiving 135 μg and 360  μg of menaquinone -7, 
respectively (Westenfeld et al. 2012 ). The results of this study provide a rationale for the use of 
plasma  PI[INVESTIGATOR_266018] -II, MGP,  and osteocalcin  as biomarkers  in an interventional  clinical  trial of vitamin 
K supplementation in hemodialysis patients.  
Fetuin A has been characterized as a critical  regulator  of calcification in humans,  and as such is 
of interest to monitor in interventions targeting calcification (Jahnen -Dechent et al., 2011 ). 
Likewise, osteoprotegerin is also thought to be a regulator of calcification, making it of interest 
here (Price et al., 2001 ). Finally, the T -[ADDRESS_323724] has been shown to correlate strongly with the 
propensity  of blood  to form calcifications,  wherein  a short  T-50 is indicative  of blood  likely  to form 
calcifications, and a lengthening of T50 for patients at risk would be desireable (Pasch et al.,  
2017 ). 
Hs-CRP  is widely  acknowledged  to be indicative  of inflammations  of various  kinds  and if elevated, 
can signal inflammatory events prior to clinical symptoms.  
 
7. OBJECTIVES  AND  ENDPOINTS  
 
This study  will evaluate  the safety and  PK of EPN-[ADDRESS_323725]  on stable 
hemodialysis.  
Primary  Objective:  
• To determine the safety and tolerability of EPN -701 (administered for two weeks at a daily 
dose of 10 mg) in subjects with ESRD on stable hemodialysis.  
Secondary  Objectives:  
• To determine,  in subjects  with ESRD  on stable  hemodialysis,  the plasma  levels  of the 
following biomarkers after two weeks of EPN -701 treatment relative to baseline:  
o Uncarboxylated  MGP  
o Uncarboxylated  osteocalcin  
o Activated  Protein  C 
o PI[INVESTIGATOR_266018] -II. 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 36  
 Exploratory  Objectives:  
• To determine  the PK profile  of EPN-[ADDRESS_323726]  on stable  hemodialysis.  
• To determine,  in subjects  with ESRD  on stable  hemodialysis,  the plasma  levels  of the 
following biomarkers after two weeks of EPN -701 treatment relative to baseline:  
o Osteoprotegerin  
o Fetuin  A 
o High-sensitivity  C-Reactive  Protein  (hs-CRP).  
o Time  to Formation  of Secondary  Calciprotein  Particles  (T-[ADDRESS_323727]);  including  CPP size. 
Specific objectives and corresponding endpoints for the study  are outlined (in Table 2 ) below.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 37  
 Table  2 Study  Objectives  and Corresponding  Endpoints  
Objectives  Corresponding  Endpoints  
Primary  Objectives:  
Safety:  
• To determine the safety and 
tolerability of EPN -701 
(administered for two weeks at a 
daily dose of 10 mg) in subjects 
with ESRD  on stable  hemodialysis.  Primary  Safety  Endpoint:  
• Frequency  of treatment -emergent  adverse  events 
(AEs) and treatment -emergent AEs assessed as 
related to the study drug (defined as possibly, 
probably, and definitely related events). A 
treatment -emergent  AE is defined  as any AE with 
an onset between the first  dose of the study drug 
and the last study visit, or any AE with an onset 
prior to the first dose that increases in severity or  
frequency  after the first dose  of study  drug.  Adverse 
events include both clinical events and laboratory 
abnormalities that are assessed as clinically 
significant.  
Secondary  Safety  Endpoints:  
• Frequency  of serious  adverse  events  (SAEs),  AEs 
leading to study drug discontinuation, and AEs of 
special interest (AESI).  
• Changes  from baseline  in laboratory  parameters  
• Changes  from baseline  in ECG  parameters  
Secondary  Objectives:  
Biomarkers:  
• To determine, in subjects with 
ESRD  on stable  hemodialysis,  the 
plasma levels of the following 
biomarkers after two weeks of 
EPN-701 treatment relative to 
baseline: uncarboxylated MGP; 
uncarboxylated osteocalcin; 
Activated Protein C; and PI[INVESTIGATOR_266018] -II 
protein.  Biomarker  Endpoints:  
• Biomarker  ratios  on Day 15 (end-of-treatment)  and 
Day 22 compared to baseline:  
o Ratio  of uncarboxylated  to total MGP  
o Ratio  of carboxylated  to uncarboxylated 
osteocalcin  
o Ratio  of carboxylated  to uncarboxylated  Protein  C 
• Plasma levels of the following biomarkers on Day 15 
(end-of-treatment)  and Day 22 compared  to baseline:  
o Uncarboxylated  MGP  
o Uncarboxylated  osteocalcin  
o Activated  Protein  C 
o PI[INVESTIGATOR_266018] -II protein  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 38  
  
Exploratory  Objectives:  
Pharmacokinetics:  
• To characterize the 
pharmacokinetic (PK) profile of 
EPN-[ADDRESS_323728] 
on stable hemodialysis.  Pharmacokinetic  Endpoints:  
• EPN-701 plasma  concentration  at each  measured 
time-point  
In addition,  depending  on the observed  plasma  levels,  the 
following PK parameters may be determined:  
• Maximum  plasma  concentration  (Cmax) [ng/mL]  
• Time  to maximum  plasma  concentration  (Tmax) [hr] 
• Area  under  the concentration -time curve  (AUC) 
from time 0 to 24 hours (AUC 0-24 [hr×ng/mL]).  
Biomarkers:  
• To determine, in subjects with 
ESRD on stable hemodialysis,  
the plasma levels of the following 
biomarkers after two weeks of 
EPN-701 treatment relative to 
baseline: osteoprotegerin, Fetuin 
A, high -sensitivity C -reactive 
protein ( hs-CRP) and Time to 
Formation of Secondary 
Calciprotein  Particles  (T-[ADDRESS_323729]); 
including CPP size.  Exploratory  Biomarker  Endpoints:  
• Plasma  levels  of the following  biomarkers  on Day 
15 (end -of-treatment) and Day 22 compared to 
baseline:  
o Osteoprotegerin  
o Fetuin  A 
o hs-CRP 
o T-[ADDRESS_323730] 
Efficacy  Objectives:  
Not applicable  Not applicable  
 
8. STUDY  DESIGN  
 
8.[ADDRESS_323731] on a stable hemodialysis 
regimen. The study will be conducted at one or two dialysis centers in the [LOCATION_002].  
A total  of 15 consenting subjects meeting the study eligibility criteria will be enrolled and treated 
with EPN -701 10 mg (one 10 mg capsule to be taken orally once a day, at the same time each 
morning, for 14 days).  
The expected  duration  of study  participation  for an individual  subject  is approximately  five weeks, 
including up to one week for screening, two weeks of study treatment, and two weeks of post - 
treatment  safety  follow -up. Subjects  will undergo  a total of 14 visits  during  their study  participation: 
Screening  visit (within  seven  days  prior to the first dose  of study  drug),  three  visits  per week  during 
the two -week treatment, and two -week safety follow -up periods (coinciding with the subject’s 
hemodialysis  schedule),  and the End-of-Study (EOS)/Early  Termination  visit. Baseline  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323732] study drug intake on Day 1. End-of-Treatment 
(EOT)  assessments  will be completed  after the last dose  of study  drug on study  Day 15 (or earlier 
in case of an early discontinuation of the study treatment). The EOS/Early Termination visit will 
occur two weeks after the last dose of study drug (on study Day 29).  
Subjects will be monitored for adverse events (AEs), and concomitant medications will be 
recorded throughout their study participation (from screening through the EOS Visit). Additional 
safety assessments will include: physical examinations, safety laboratory tests (hematology, 
including complete blood count [CBC]; complete metabolic panel [CMP, including electrolytes, 
renal and liver function tests, and lipid profile]; and coagulation panel), and 12 -lead 
electrocardiogram (ECG). In addition, occurrence of dialyzer clotting will be assessed at each 
dialysis  session,  and Kt/V (a standard  measure  of dialysis  adequacy)  will be calculated  at baseline 
(as the average of  the last  three pre -study  Kt/V values obtained as part  of the subject’s standard 
of care), and at EOT (Day 15).  
Blood for PK assessments will  be sampled pre -dose (pre -dialysis) and post -dose (during and/or 
at the end of dialysis/before needle removal) on Days 1, 3, 5, 8, 10, 12, and 15, and pre -dose 
only on Day 17.  
Pre- and post-dialysis  blood  samples  for biomarker  analyses  will be collected  at Baseline,  and on 
select Mondays during the two -week treatment, and two -week safety follow -up periods.  
Refer  to Table  1, Schedule  of Study  Activities  for further  details.  
8.1.[ADDRESS_323733] of assessments  to be 
completed at each study visit is provided in Section  9.5. 
8.1.2  Study  Committees  
 
An SRC will review the safety data accumulated during the study at regular intervals. The SRC 
will be comprised of the Sponsor’s Medical Monitor, Independent Medical Monitor, and the 
Principal Investigator. Further details will be provided in the SRC Charter.  
 
 
8.[ADDRESS_323734] visit (LSLV), which is expected 
approximately  six to seven  months  after the enrollment  of the first subject  (“first  subject  in” [FSI]). 
The actual length of the study will depend on the actual recruitment rate.  
In addition,  the Sponsor  may decide  to terminate  the study  at any time (see Section  9.7.3). 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323735]  meet  all inclusion  criteria  to be enrolled  in the study:  
1. Male  or female  ≥[ADDRESS_323736] 
missed  (less  than or equal  to) [ADDRESS_323737],  as judged  by [CONTACT_266068] (physical  examination, medical  history, clinical 
laboratory tests, vital signs, and 12 -lead ECG).  
4. Written  informed  consent  
5. Able and willing  to comply  with the requirements  of the study  protocol  
6. For females  of child-bearing  potential:  
o Negative  serum  pregnancy  test; 
o Abstinence (refraining from heterosexual intercourse) or use of an acceptable 
contraception for at least [ADDRESS_323738] -menarche, has not 
reached a postmenopausal state (  12 continuous months of amenorrhea with no identified 
cause other than menopause), and has not undergone surgical sterilization (removal of 
ovaries and/or uterus, or bilateral tubal ligation).  
Examples of  acceptable contraceptive methods include:  hormonal  contraceptives that inhibit 
ovulation, hormone -releasing intrauterine devices, and copper intrauterine devices.  
9.1.2  Exclusion Criteria  
 
Subjects  meeting  any of the following  exclusion  criteria  will be excluded  from the  study:  
1. Chronic  kidney  disease  not requiring  hemodialysis  
2. Acute  kidney  injury  treated  with hemodialysis  
3. Diagnosis  of confirmed  calciphylaxis  
4. History  of any solid organ  transplant  
5. History  of malignancy  within  2 years  of study  enrollment,  except  for adequately  treated 
carcinoma in situ of the cervix and non -melanoma skin carcinoma.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 41  
 6. History of any major surgery (defined as a surgical procedure involving the cranium, chest, 
abdomen, or pelvic cavity, or other procedure performed under general anesthesia) within [ADDRESS_323739] dose of study drug. Subjects with a recent (within <1 month) revision 
and/or placement of arteriovenous fistula (AVF) will be allowed to participate.  
7. History of a major cardiovascular event (such as cerebrovascular accident [CVA], transient 
ischemic attack [TIA], myocardial infarction,  unstable angina)  within [ADDRESS_323740] 
dose of study drug.  
8. Any co -existing disease or condition that may compromise the safety of study participants 
and/or the integrity of the study, including, but not limited to:  
o Class  C or Class  D Cirrhosis  of the liver 
o Known  intestinal  malabsorption  
o Inability  to take oral medication  
9. Life-expectancy  <3 months  
10. Known history or positive serology for Human Immunodeficiency Virus (HIV), positive 
serologies  of E antigen  or with polymerase  chain  reaction  (PCR)  positive  titers  for hepatitis  B 
virus  (HBV).  Subjects  with positive  serologies  for hepatitis  C but with negative  PCR  for active 
virus will be allowed.  
11. Severe infection requiring intravenous (IV)  antibiotics within two weeks prior  to the first  dose 
of study drug.  
12. Warfarin taken within two weeks prior to the first dose of study drug. Subcutaneous heparin, 
enoxaparin and novel oral anticoagulants (NOAC; such as api[INVESTIGATOR_3822]) are permitted.  
13. Treatment  with an investigational  drug within  four weeks  prior to the first dose  of study  drug.  
14. Pregnancy  or lactation.  
15. Any other disease or condition which, in the judgment of the Investigator, would place a 
subject at undue risk by [CONTACT_266069], or cause inability to comply with the trial.  
 
9.2 METHOD  OF TREATMENT ASSIGNMENT  AND  BLINDING  
 
9.2.1  Randomization  and Blinding  
 
Not applicable;  this is  a non-randomized,  uncontrolled,  open  label  study.  
9.2.[ADDRESS_323741] will be 
assigned a unique identification number.  
 
9.3 STUDY  DRUG:  EPN-701 
 
The term "study  drug"  or “test product”  is used  throughout  this protocol  to refer to EPN-701. 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 42  
 There  is no comparator  and no other  medication  use is mandated  by [CONTACT_760].  All concomitant 
medications will be recorded in the electronic Case Report Form (eCRF).  
9.3.[ADDRESS_323742] is formulated as oral  soft-gel capsules. Each capsule contains 10  mg of active 
ingredient.  
Further  details  are provided  in the EPN-701 Investigator’s  Brochure.  
9.3.[ADDRESS_323743] will be packaged and labeled by  [CONTACT_266070] (San Diego, CA). The recommended storage condition for the bottled finished 
product soft gels is15 –30 °C (59 -86 °F) (controlled room temperature).  
The Investigator has overall responsibility for ensuring that study drug is stored in a secure, 
limited -access location. Limited responsibility may be delegated to the research pharmacy or 
member of the study team, but this delegation must be documented.  
The study  drug must  be stored  in accordance  with labeled  storage  conditions.  
9.3.3  Study  Drug  Labeling  
 
Each container of study drug will be clearly labeled with study -specific information meeting all 
applicable regulatory requirements. Clinical trial drug supply labels may bear the following 
information:  
• Statement  indicating  that the product  is limited  by [CONTACT_194271] 
• Name,  number,  or identifying  mark  of the study  drug and quantity  of drug in each  unit 
• Manufacturing  date or expi[INVESTIGATOR_266026]-test date 
• Recommended  storage  conditions  for the study  drug 
• Study  drug lot number  
• Protocol  code  or study  identification  
• Name [CONTACT_266113].  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 43  
 9.3.4  Study  Drug  Dispensing  
 
The Investigator  has overall  responsibility  for administering/dispensing  the investigational  product. 
Where permissible, tasks may be delegated to a qualified designee (e.g., a pharmacist) who is 
adequately  trained  in the protocol  and who works  under  the direct  supervision  of the Investigator. 
This delegation must be documented in the applicable study delegation of authority form.  
The Investigator or his/her designee (as documented by [CONTACT_266071]) will  administer the study  drug only to subjects included in this study 
who have (1) signed the current study -specific informed consent form (ICF); (2)  completed all 
screening assessments and requirements; and (3) met all eligibility criteria for initiation of study 
treatment.  
Each subject  will be given  sufficient  study  drug to  carry  for two weeks.  The pharmacist/designee 
will enter  the unique  subject  identifier  and initials  on the investigational  product  bottle/carton  label 
as they are dispensed. At each visit during the treatment period, the study coordinator will verify 
that the subject is taking the study drug as specified in the protocol.  
9.3.[ADDRESS_323744] in this study, will be provided by [CONTACT_266072]:  
• [ADDRESS_323745]  will take one 10 mg capsule  of EPN-701 per day orally  over 14 days.  
The study  drug is to be taken at  the same  time each  morning.  On hemodialysis days (Days 1,  3, 
5, 8, 10, and 12), subjects will take their study drug dose pre -dialysis (immediately after needle 
placement  and biomarker  sampling,  as applicable);  on the remaining  days  during  Weeks  [ADDRESS_323746] be assessed at the container/packaging 
level for unused investigational product that is contained within the original packaging, or at the 
individual  count  level for opened  bottles.  The pharmacist/designee  will record  details  on the Study 
Drug Accountability Form.  
9.3.[ADDRESS_323747] dispensed, used, 
returned, and/or destroyed must be maintained as detailed further in this section.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323748]’s drug accountability source 
documentation. Doses taken at home (including date, time, and amount taken) will be 
documented  by [CONTACT_266073].  Subjects  will be asked  to return 
the completed  Study  Drug  Home  Intake  Form  to the clinic  at each  scheduled  visit so that the study 
coordinator  can document  all study  drug intakes  in the subject’s  source  documents  and enter  on 
the e -CRF. The final Study Drug Home Intake Form will be collected from the subject after the 
last dose has been taken and will be placed in the subject’s study chart. The CRA will verify the 
study drug eCRF entries against the Study Drug Accountability Form and source documents to 
ensure consistency.  
No investigational  product stock or returned inventory from this study may be removed from the 
site where  originally  shipped  without  prior knowledge  and consent  by [CONTACT_1034].  If such  transfer 
is authorized  by [CONTACT_1034],  all applicable local,  state,  and national  laws must  be adhered  to for 
the transfer.  
The Sponsor  or its representatives  must  be permitted access to review  the supplies storage  and 
distribution procedures and records.  
At the end of the study, or as instructed by [CONTACT_1034], all unused stock, and empty/used 
investigational product packaging are to be sent to a designated contractor on behalf of the 
Sponsor.  Investigational  product  being  returned  to the Sponsor’s  designated  contractors  must  be 
counted  and verified  by [CONTACT_266074]  (or designated  Contract  Research 
Organization [CRO]). For unused supplies where the original supplied tamper -evident feature is 
verified  as intact,  the tamper -evident  feature  must  not be broken,  and the labeled  amount  is to be 
documented in lieu of counting. All certificates of delivery/drug receipts should be signed by [CONTACT_266075]. Shipment return forms, when used,  must be 
signed prior to shipment from the site. Returned investigational product must be packed in a 
tamper -evident  manner  to ensure  product  integrity.  The Sponsor  must  authorize  the return  of any 
investigational product prior to shipment. Shipment of all returned investigational product must 
comply with local, state, and national laws.  
All study  drugs  received  at, dispensed  from,  returned  to, and disposed  of by [CONTACT_266076].  
9.3.[ADDRESS_323749] -Trial  Access  to EPN-701 
 
Not applicable.  
 
9.4 CONCOMITANT  THERAPY  
 
Concomitant therapy consists of any medication (e.g., prescription and over -the-counter drugs, 
vaccines, and nutritional supplements) used by a subject in addition to the study drug from the 
screening to the EOS/Early Termination visit. All such medications should be recorded on the 
Concomitant Medications eCRF.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 45  
 9.4.1  Prohibited  Therapy  
 
Patients receiving long -term warfarin (Coumadin) frequently develop asymptomatic excessive 
prolongation of their international normalized ratio (INR) results. The anticoagulant effect of 
warfarin, functioning by [CONTACT_266077] K, can be offset with as 
little as 1 mg of vitamin  K (Crowther  et al. 1998 ). Therefore,  use of vitamin  K is contraindicated  in 
individuals on warfarin therapy (Vitamin K2 Monograph, 2009 ). 
Medications  that are prohibited  while  the subject  is receiving  study  drug are listed  in Table 3. 
 
Table  [ADDRESS_323750] Dose of 
Study Drug  
Any investigational therapy  4 weeks  
Warfarin*  2 weeks  
IV antibiotics  2 weeks  
Prescription  and non-prescription  medications  known  to be 
sensitive substrates of CYP3A** or CYP4F2***  None  
Herbal and  homeopathic  remedies  None  
Abbreviations:  IV=intravenous  
* Subcutaneous  heparin,  enoxaparin  and novel  oral anticoagulants (NOAC;  such as api[INVESTIGATOR_3822])  are 
permitted.  
** As listed  in the FDA Drug  Development and  Drug  Interactions:  Table  of Substrates,  Inhibitors  and 
Inducers (2017 ) 
*** Example:  fingolimod  
 
 
The investigator  should contact  [CONTACT_266078].  
[IP_ADDRESS]  Herbal  Therapi[INVESTIGATOR_266027].  
9.4.[ADDRESS_323751].  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323752] - 
treatment safety follow -up. 
Subjects will undergo a total of 14 visits during their study participation: Screening visit (within 
seven days prior to the first dose of study drug), three visits per week during the two -week 
treatment, and two -week safety follow -up periods (coinciding with the subject’s hemodialysis 
schedule),  and the EOS/Early  Termination  visit. Baseline  assessments  will be completed  prior to 
the first study drug intake on Day 1. The EOS/Early Termination visit will occur two weeks after 
the last dose of study drug (on study Day 29).  
Subjects will be closely monitored for safety and tolerability throughout the study. At each 
treatment visit, assessments should be completed prior to the study drug administration, unless 
otherwise stated.  
At each study visit, subjects will also undergo hemodialysis, as per their standard ESRD 
management;  hemodialysis is  therefore  not listed  as a study -related  assessment  in the  following 
sections.  
9.5.1  Screening  Visit  (Day  -7 to Day  -1) 
 
Subjects  will undergo  the following  assessments  during  screening:  
• Obtaining informed  consent  and Health Insurance Portability and Accountability  Act (HIPAA) 
authorization (see Section  9.6.1  for details)  
• Review  of eligibility  (inclusion  and exclusion)  criteria  (see Sections  9.1.1  and 9.1.2  for details)  
• Recording of general  medical  history (including menstrual  history for females of childbearing 
potential), disease history, and demographics (see Section  9.6.2  for details)  
• Recording  of baseline  and concomitant  medications  (see Section  9.6.3  for details)  
• Complete physical examination, measurement of height and weight (see Section  9.6.4  for 
details)  
• Standard  12-lead ECG  within  60 minutes  pre-dialysis  (see Section  9.6.6  for details)  
• Measurement of vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and oral body 
temperature (pre -dialysis) (see Section  9.6.5  for details)  
• Testing  for HIV, hepatitis  B and C (see Section  [IP_ADDRESS]  for details)  
• Collection of blood samples for safety laboratory tests pre -dialysis (hematology, CMP, 
coagulation panel, and serum β -hCG pregnancy test (females of childbearing potential  only) 
(see Section  [IP_ADDRESS]  for details).  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 47  
 9.5.2  Visit  1 (Day  1, Baseline),  Visit  4 (Day  8), Visit  7 (Day  15, End-of- 
Treatment), and Visit 10 (Day 22) [Mondays]  
 
Subjects  will undergo  the following  assessments  during  these  visits:  
• (At baseline/Visit 1 only:) Review of eligibility (inclusion and exclusion) criteria (see Sections  
9.1.1  and 9.1.2  for details)  
• Recording  of any changes  in concomitant  medications  (see Section  9.6.3  for details)  
• (At Visit 7 only, if clinically indicated:) Symptom -driven physical examination (see Section  
9.6.4  for details)  
• (At Visits  1, 4, and 7): Measurement  of body  weight within [ADDRESS_323753] -dialysis (see Section  9.6.4  for details)  
• (At Visit 7 only): Standard 12 -lead ECG within 60 minutes pre -dialysis (see Section  9.6.6  for 
details)  
• (At Visits  1, 4, and 7): Measurement  of vital signs  (blood  pressure,  heart  rate, respi[INVESTIGATOR_2842], 
and oral body  temperature  within [ADDRESS_323754]-dialysis 
(see Section  9.6.5  for details)  
• Collection of blood samples for safety laboratory tests pre -dialysis (hematology, CMP, 
coagulation panel) (see Section  [IP_ADDRESS]  for details)  
• (At Visits 1, 7, and 10): Collection of blood samples for biomarker assessments pre -dialysis 
(pre-dose) (see Section  [IP_ADDRESS]  for details):  
o MGP, osteocalcin, Protein C, PI[INVESTIGATOR_266018] -II protein, Fetuin A, osteoprotegerin, hs-CRP, and 
Time to Formation of Secondary Calciprotein Particles (T -[ADDRESS_323755]); including CPP size.  
• Collection of blood samples for PK assessments pre -dialysis/pre -dose (at the time of needle 
placement)  (Visits  1, 4, and 7), during  dialysis  (Visits  1 and 4) and at the end of dialysis  (before 
needle removal) (Visits 1, 4 and 7) (see Section  [IP_ADDRESS]  for details)  
• (At Visits 1 and 4 only): Study drug administration pre -dialysis (immediately after needle 
placement and the pre -dialysis biomarker sampling) (see Section  9.3.5  for details)  
• Recording  of changes  in baseline  complaints  under  general  medical  history  (events  occurring 
before the first  dose of  study  drug [Visit  1 only]; see Section  9.6.2  for details)  or AEs (events 
occurring after the first dose of study drug [Visit [ADDRESS_323756] -dose and subsequent visits]; see 
Section  10.3 for details). Any occurrence of dialyzer clotting (assessed at each dialysis 
session) is to be recorded as an AE (see Section 10.3.2 ). 
• Kt/V will be calculated at baseline as the average of the last three pre -study Kt/V values 
obtained as part of the subject’s standard of care. At Visit 7, Kt/V will be measured and 
compared with the baseline value.  
Assessments completed after the last dose of study drug on study Day 15/Visit 7 (or earlier in 
case of an early discontinuation of the study treatment) will be considered EOT assessments.  
At the end of Visit 1, subjects will receive a sufficient supply of the study drug for two weeks of 
treatment.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 48  
 9.5.3  Visits 2 & 3 (Days 3 & 5), Visits 5 & 6 (Days 10 & 12), Visits 8 & 9  
(Days  17 & 19), and Visits  11 & 12 (Days  24 & 26) [Wednesdays  & 
Fridays]  
 
Subjects  will undergo  the following  assessments  during  these  visits:  
• Recording  of any changes  in concomitant  medications  (see Section  9.6.3  for details)  
• Recording  of AEs (see Section  10.3 for details).  Any occurrence  of dialyzer  clotting  (assessed 
at each dialysis session) is to be recorded as an AE (see Section 10.3.2 ). 
• (At Visits 2, 3, 5, and 6): Measurement of body weight within [ADDRESS_323757] -dialysis (see Section  9.6.4  for details)  
• (At Visits 2, 3, 5, and 6): Measurement of vital signs (blood pressure, heart rate, respi[INVESTIGATOR_862], and oral body temperature within [ADDRESS_323758] - 
dialysis (see Section  9.6.5  for details)  
• (Visits 2, 3, 5, and 6 only:) Study drug administration pre -dialysis (immediately after needle 
placement) (see Section  9.3.5  for details)  
• Collection of blood samples for PK assessments pre -dialysis/pre -dose (at the time of needle 
placement)  (Visits  2, 3, 5, 6, and 8), and at the end of dialysis  (before  needle  removal)  (Visits 
2, 3, 5, and 6) (see Section  [IP_ADDRESS]  for details).  
9.5.4  End-of-Study/Early  Termination  Visit  (Day  29) 
 
Subjects  will undergo  the following  assessments  during  these  visits:  
• Recording  of any changes  in concomitant  medications  (see Section  9.6.3  for details)  
• Recording  of AEs (see Section  10.3 for details)  
• Complete  physical  examination  (see Section  9.6.4  for details)  
• Standard  12-lead ECG  within  60 minutes  pre-dialysis  (see Section  9.6.6  for details)  
• Measurement of body weight within [ADDRESS_323759] - 
dialysis (see Section  9.6.4  for details)  
• Measurement of vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and oral body 
temperature within [ADDRESS_323760] -dialysis (see Section  
9.6.5  for details)  
• Collection of blood samples pre -dialysis for safety laboratory tests (hematology, CMP, 
coagulation panel) (see Section  [IP_ADDRESS]  for details).  
 
9.[ADDRESS_323761] or procedure. The investigator will 
maintain a log of all subjects who consented to participating in the study.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 49  
 9.6.2  Medical  History  and Demographic  Data  Collection  
 
Details of the underlying condition (including ESRD and dialysis history), as well as general 
medical  history  (including  clinically  significant  diseases  or conditions,  surgeries,  and reproductive 
status), will be recorded at screening/baseline. Baseline complaints (symptoms or adverse 
experiences  present  prior to the  first dose  of study  drug)  will also be recorded  as medical  history.  
Demographic  data will include  age, sex, and self-reported  race/ethnicity.  
9.6.3  Baseline  and Concomitant  Medications  
 
All medications (including over -the-counter medications) or therapy administered to the subject 
during the [ADDRESS_323762] dose of study drug will be recorded at screening/baseline 
(including start date, medication name, dosage, frequency, and route of administration). Any 
contraindicated medications will be stopped or replaced by [CONTACT_266079] -specified wash -out period (refer to Section  9.4.1  for 
details).  
Any changes  to concomitant  medications  will be documented  regularly  throughout  the study.  
9.6.4  Physical  Examinations  and Measurements  
 
A complete  physical  examination  (including  a review  of the main  body  organs  and systems)  must 
be conducted  at screening  and the EOS/Early  Termination  visit (Day  29). In addition,  a symptom - 
driven (abbreviated) physical  exam may be performed at the End -of-Treatment (EOT) visit (Day 
15), if the investigator deems it clinically indicated; see Table 1 . 
Any treatment -emergent  clinically  significant  physical  examination  findings  should  be recorded  as 
adverse events on the Adverse Event CRF.  
Subjects  will also undergo  body  weight  and height  measurement  at screening/baseline,  and body 
weight measurements (as part of their standard care on dialysis days) within [ADDRESS_323763] -dialysis on each dialysis day during the 2 -week treatment 
period  (Visits  1 through 6),  at the EOT visit (Day  15), and at the EOS  visit (Day  29); see  Table 1 . 
9.6.5  Vital Signs  Measurements  
 
Vital signs (including blood pressure,  heart  rate, respi[INVESTIGATOR_2842], and oral  body  temperature)  will 
be measured  at screening,  and (as part of their standard  care on dialysis  days)  within  [ADDRESS_323764]-dialysis  at each  treatment  visit (Visits  1 through  6), at the 
EOT visit (Day  15), and at the EOS  visit (Day  29); see Table  1. Any treatment -emergent  clinically 
significant  vital signs abnormalities should  be recorded  as adverse events on the  Adverse Event 
CRF.  
9.6.[ADDRESS_323765]  12-lead ECG recordings  will be obtained  within 60 minutes  pre-dialysis  at 
screening/baseline,  at the EOT visit (Day  15), and at the EOS  visit (Day  29); see Table  1. ECG  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323766] 
5 minutes, and prior to other procedures scheduled at that same time (e.g., blood draws).  
The Principal Investigator [INVESTIGATOR_266028], interpret sign, and date all ECG tracings. ECG 
abnormalities must be documented on the CRF and assessed for clinical significance. All 
treatment -emergent clinically significant ECG abnormalities must be reported as AEs.  
Paper  copi[INVESTIGATOR_266029]'s  file at the site. 
9.6.7  Assessment  of Dialysis  Adequacy  (Kt/V)  
 
Kt/V is a standard  measure  of dialysis  adequacy,  where  K stands  for the dialyzer  urea clearance, 
t stands for the duration of the dialysis session, and V stands for the volume of urea distribution 
(roughly corresponding to the volume of water contained in the patient's body).  
As part of the safety evaluations, Kt/V will be measured at EOT (Day 15), and compared to the 
baseline value, which will be calculated as the average of the last three pre -study Kt/V values 
obtained as part of the subject’s standard of care. In case the Kt/V value obtained at EOT is 
reduced compared to baseline (pre -study measurements), the Investigator will determine (in 
consultation with the Medical Monitor, as needed) if the event qualifies for reporting as an AE.  
9.6.8  Laboratory,  Biomarker,  and PK Samples  
 
The assessments  listed  in this section  will be performed  at Covance  Central  Laboratory  Services 
(Covance). Instruction manuals and supply kits will be provided by [CONTACT_266080].  
An overview of the standard safety laboratory, biomarker, and PK sampling requirements is 
provided below. For additional details on laboratory assessments and sample handling, refer to 
the laboratory manual.  
[IP_ADDRESS]  Safety  Laboratory  Assessments  
 
Samples  for the following  safety  laboratory  tests  will be sent to the central  laboratory  for analysis:  
• Hematology  panel: red blood cell (RBC)  count, hemoglobin, hematocrit, and white blood cell 
(WBC) count, with differential (neutrophils, eosinophils, lymphocytes, monocytes, basophils, 
and other cells), if clinically indicated.  
• Complete  Metabolic  Panel  (CMP):  
o Glucose,  albumin,  total protein;  
o Electrolytes:  sodium,  potassium,  bicarbonate,  chloride,  calcium,  magnesium,  phosphate;  
o Renal  function  tests:  blood  urea nitrogen  (BUN),  creatinine;  
o Liver  function  tests:  (ALT,  AST,  bilirubin),  and 
o Lipid  profile:  total cholesterol,  low-density  lipoprotein  (LDL)  cholesterol,  high-density 
lipoprotein (HDL) cholesterol, and triglycerides (TG).  
• Coagulation  panel  includes:  partial  thromboplastin  time (PTT),  INR, and platelet  count.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 51  
 All blood  sampling  will occur  pre-dialysis  (at the time of needle  placement). 
In addition, all subjects will undergo the following tests at screening only:  
• Serology  for: 
o HIV 
o HBV:  hepatitis  B “e” antigen  (HBeAg)  and PCR  for the active  virus  (HBV  deoxyribonucleic 
acid [DNA]); and  
o HCV:  HCV  antibody  and PCR  for active  virus  (HCV  ribonucleic  acid [RNA])  
• For women  of child bearing  potential  only:  serum  beta-human  chorionic  gonadotropin  (β-hCG) 
pregnancy  test (the results of  the screening pregnancy  test must  be negative for  enrolment).  
The schedule for laboratory assessments is provided in Table 1 . All baseline laboratory 
assessments  may occur  during  screening  (within  [ADDRESS_323767] dose  of the study  drug).  
The total volume of blood drawn from each subject for safety laboratory assessment will be 
approximately 57 mL over the course of the study. Instructions for safety laboratory specimen 
collection,  handling,  and shippi[INVESTIGATOR_266030] (Covance).  
[IP_ADDRESS]  Biomarker  Assessments  
 
Blood  samples  will be obtained  for biomarker  evaluation  according  to the schedule  in Table 1 and 
Table  4. Serially  collected  blood  samples  will be processed  to obtain  plasma  for the determination 
of the following biomarkers:  
• Uncarboxylated MGP; uncarboxylated osteocalcin; Activated Protein C, PI[INVESTIGATOR_266018] -II protein; 
Fetuin A, osteoprotegerin, hs-CRP, and Time to Formation of Secondary Calciprotein 
Particles (T -[ADDRESS_323768]); including CPP size.  
Blood sampling for biomarker analysis will always occur pre -dialysis (at the time of needle 
placement): on Day 1 (Baseline), Day 15 (EOT), and Day 22 ([ADDRESS_323769] study drug 
dose).  
The total volume of blood drawn from each subject for biomarkers assessment will be 
approximately 48 mL over the course of the study (approximately 16 mL per assessment time - 
point). Instructions for biomarker specimen collection, handling, and shippi[INVESTIGATOR_266031] (Covance).  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 52  
 Table  4 Biomarker  Assessments  
 
Sample 
Type   
Timing   
Biomarkers  
Blood  Day 1, pre-dialysis*  
(Week  1, Baseline)  Uncarboxylated MGP; unccarboxylated osteocalcin, 
Activated Protein C, PI[INVESTIGATOR_266018] -II protein, Fetuin A, 
osteoprotegerin, hs-CRP, and Time to Formation of 
Secondary  Calciprotein  Particles  (T-[ADDRESS_323770]);  including  CPP 
size. 
Blood  Day 15, pre-dialysis* 
(EOT)  Uncarboxylated MGP; unccarboxylated osteocalcin, 
Activated Protein C, PI[INVESTIGATOR_266018] -II protein, Fetuin A, 
osteoprotegerin, hs-CRP, and Time to Formation of 
Secondary  Calciprotein  Particles  (T-[ADDRESS_323771]);  including  CPP 
size. 
Blood  Day 22, pre-dialysis*  
([ADDRESS_323772] 
study drug dose)  Uncarboxylated MGP; unccarboxylated osteocalcin, 
Activated Protein C, PI[INVESTIGATOR_266018] -II protein, Fetuin A, 
osteoprotegerin, hs-CRP, and Time to Formation of 
Secondary  Calciprotein  Particles  (T-[ADDRESS_323773]);  including  CPP 
size. 
CPP=calciprotein  particles;  EOT=end -of-treatment;  hs-CRP=  high-sensitivity  C-Reactive  Protein; 
MGP=matrix gamma -carboxyglutamic acid (Gla) protein; PI[INVESTIGATOR_266018] -II=Protein Induced in Vitamin K 
Absence/Antagonist -II; T-50=Time to Formation of Secondary Calciprotein Particles.  
* Pre -dialysis=at  the time of needle  placement  
 
[IP_ADDRESS]  Pharmacokinetic  Assessments  
 
Blood  for PK assessments  will be sampled  as follows:  
• On Visit 1/Day  1 (baseline)  and Visit 4/Day  8 (Week  2, on-treatment):  pre-dialysis  (at the time 
of needle  placement;  denoted  as 0 hours),  followed  by [CONTACT_266047],  and then at 
1 hour (+/- 5 minutes),  2 hours  (+/- 5 minutes),  3 hours  (+/- 5 minutes),  4 hours  (+/- 30 
minutes)/before needle removal, 6 hours (+/ - 30 minutes), 8 hours (+/ - 30 minutes), and 24 
hours (+/ - 60 minutes) after study drug administration;  
• On Visit 2/Day  3, Visit 3/Day  5, Visit 5/Day  10, Visit 6/Day  12, and Visit 7/Day  15: pre-dialysis 
(at the time of needle placement, at 0 hours), immediately followed by [CONTACT_266081], and then at 4 hours (+/ - 30 minutes)/ before needle removal; and  
• On Visit 8/Day  17 (Week  3, off-treatment):  pre-dialysis  only (at the time of needle  placement).  
The timing  and sequence  of PK blood  sample  collections  relative  to the study  drug administrations 
and dialysis will be as follows:  
• PK samples taken pre -dialysis (pre -dose; at 0 hour): Samples will be collected after needle 
placement and will be immediately followed by [CONTACT_266082]. Immediately 
following drug administration, dialysis is to be started.  
• PK samples taken during dialysis (post -dose): Samples will be collected at 1 hour (+/ - 5 
minutes), 2 hours (+/ - 5 minutes) and 3 hours (+/ - 5 minutes) after the 0 -hour PK time -point.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323774] -Dialysis  
 
 
Study 
Drug  
 Needle 
Placement  • PK samples taken post -dialysis (post -dose): Samples will be collected when the dialysis is 
completed (before needle removal) or at 4 hours (+/ - 30 minutes) after the [ADDRESS_323775].  
• Note:  The duration  of dialysis  sessions  is expected  to be approximately  4 hours;  however,  the 
actual duration should not have an impact on the PK sample collection time -points.  
The calendar  date and actual  clock  time will be recorded  for each  PK blood  sample  collection  and 
the actual elapsed time from dosing will be used for the PK calculations.  
Refer  to Figure  5 for further  details.  
 
Figure  5 – Sequence  of PK Sampling,  Visits  1 – 8 
 
 
0-hr PK  1-hr PK  2-hr PK  3-hr PK  4-hr PK  6-hr PK  8-hr PK  24-hr PK 
Sample   Sample   Sample   Sample   Sample   Sample   Sample   Sample  
               
Visits   Visits   Visits   Visits   Visits   Visits   Visits   Visits  
1 - 8  1 & 4  1 & 4  1 & 4  1 - 7  1 & 4  1 & 4  1 & 4 
 
 
Plasma samples will be assayed for EPN -701 concentrations (ng/mL) according to standard 
procedures, using a validated high -performance liquid chromatography (HPLC) tandem mass 
spectrometric (LC/MS/MS) method.  
Apart  from the  plasma concentrations at  each time -point,  depending on the observed levels,  the 
following PK parameters may also be determined:  
• Maximum  plasma  concentration  (Cmax) [ng/mL]  
• Time  to maximum  plasma  concentration  (Tmax) [hr] 
• Area  under  the concentration -time curve  (AUC)  from time 0 to 24 hours  (AUC 0-24 [hr×ng/mL]).  
The total volume  of blood  drawn  from each  subject  for PK assessment  will be approximately  108 
mL over the course  of the study  (approximately  4 mL per assessment  time-point).  Instructions  for 
PK specimen  collection,  handling,  and shippi[INVESTIGATOR_266032] (Covance).  
9.6.9  Efficacy  Evaluations  
 
Not applicable.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323776] stops taking the study drug.  
Potential  reasons  for permanent  discontinuation  of the study  drug are detailed in  Section  [IP_ADDRESS] . 
The primary reason for study drug discontinuation should be documented on the appropriate 
eCRF  along  with the date of stoppi[INVESTIGATOR_266033],  and the total amount  of the study  drug taken. 
If the study drug is discontinued, regardless of the reason, the end -of-treatment evaluations are 
to be performed as completely as possible.  
9.7.[ADDRESS_323777] at any time (e.g., in the interest of subject safety).  
To the extent feasible, all withdrawn subjects should undergo the protocol -specified post - 
treatment  follow -up. However,  subjects  will not be followed  for any reason  after consent  has been 
withdrawn.  
The reason  for withdrawal  from the study  must  be determined  by [CONTACT_266083]’s  medical  record  and on the eCRF.  If a subject  is withdrawn  for more  than one reason, 
each reason should be documented in the source document and the most clinically relevant 
reason  should  be entered  on the eCRF.  If an AE is (one of) the reason(s)  for discontinuation,  then 
“Adverse  event”  must  be recorded  as the reason  for discontinuation  on the eCRF.  Any comments 
(spontaneous or elicited) pertinent to the withdrawal or complaints made by [CONTACT_38885].  
[IP_ADDRESS]  Reasons  for Study  Drug  Discontinuation  and Withdrawal  
 
Reasons  for discontinuation  from the study  drug and for withdrawal  from the study  include  but are 
not limited to:  
• Adverse  event  
• Any medical  condition  that may jeopardize  the subject’s  safety  
• Significant  worsening  in the subject’s  underlying  condition  
• Withdrawal  of consent  by [CONTACT_423]  
• Protocol  violation (such as subject non -compliance with the study drug or study procedures, 
use of prohibited medication)  
• Subject  lost to follow -up 
• Pregnancy.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323778]’s  last known  address  via courier  or mail 
with an acknowledgement of receipt request.  
[IP_ADDRESS]  Replacement  of Subjects  
 
Subjects  prematurely  discontinuing  study  drug or withdrawing  from the  study  (while on  treatment 
or during the  2-week  post-treatment  safety  follow -up) may be replaced  if the following  criteria  are 
met: 
• If a subject  discontinues  study  drug or withdraws  from the  study  for any reason  on or before 
Day 22.  
• If a subject  misses  a visit(s)  due to non-compliance,  SAE and/or  hospi[INVESTIGATOR_266034] a critical 
PK and/or biomarker timepoint(s) as it relates to the study endpoint.  
A decision to replace subject(s) will be determined by [CONTACT_266084]/Site with rationale and further instruction, as applicable.  
9.7.3  Study  Discontinuation  
 
The Sponsor  has the right to terminate  this study  at any time.  The Sponsor  will notify  the 
investigator(s) in case a decision is made to discontinue the study.  
9.7.4  Site Discontinuation  
 
The Sponsor  has the right to close  a site at any time.  Reasons  for closing  a site may include,  but 
are not limited to, the following:  
• Excessively  slow recruitment  
• Poor  protocol  adherence  
• Inaccurate  or incomplete  data recording  
• Non-compliance with the International Council for Harmonization (ICH) guideline for Good  
Clinical Practice  
• Study  activities  completed  (i.e., all subjects  have  completed  the study  and all obligations  have 
been fulfilled.).  
 
10. ASSESSMENT  OF SAFETY  
 
10.1 DEFINITIONS  
 
An Adverse Event (AE) is any untoward medical occurrence in a clinical investigation subject 
administered a pharmaceutical  product and that does not necessarily  have  a causal  relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal  laboratory  finding),  symptom,  or disease  temporally  associated  with the use of a 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 56  
 medicinal (investigational) product, whether related to the medicinal (investigational) product or 
not (ICH Guidance E2A 1994 ). 
Treatment -emergent AEs are defined as  any AE with an onset  between the first  dose of  the 
study  drug and the last study  visit, or  any AE with an onset  prior to  first dose  that increases  in 
severity or frequency after the first dose of study drug.  
A Serious  Adverse  Event  (SAE)  is any untoward  medical  occurrence  (whether  considered  to be 
related to investigational product or not) that at any dose:  
• Results  in death  
• Is life-threatening  [1] 
• Requires  inpatient  hospi[INVESTIGATOR_40088]  [2] 
• Results in  persistent  or significant  disability/incapacity  
• Is a congenital  abnormality/birth  defect  
• Is an important  medical  event  [3] 
[1] The term ‘life-threatening’  in the definition  of ‘serious’  refers  to an event  in which  the subject  was at 
risk of death at the time of the event; it does not refer to an event which hypothetically might have 
caused death if it was more severe.  
[2] Hospi[INVESTIGATOR_266035] -existing 
conditions, where such conditions have not worsened after initiation of treatment, should not be 
classified as SAEs. For example, an admission for a  previously scheduled ventral hernia repair would 
not be classified as an SAE. However, complication(s) resulting from a hospi[INVESTIGATOR_266036](s).  
[3] Important  medical  events  that may not result  in death,  be life-threatening,  or require  hospi[INVESTIGATOR_266037],  based  upon  appropriate  medical  judgment,  they may jeopardize  the 
subject and may require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home; blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency or drug abuse.  
Note:  
The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an 
adverse  event  (e.g.,  rated  as mild,  moderate,  or severe;  see Section  [IP_ADDRESS] ); the event  itself 
may be of relatively  minor  medical  significance  (such  as severe  headache  without  any further 
findings). Severity and seriousness need to be independently assessed for each adverse 
event recorded on the eCRF.  
Adverse  events  of special  interest  (AESI):  An adverse  event  of special  interest  (serious  or non- 
serious)  is one of scientific and  medical  concern  specific  to the  sponsor’s  product  or program,  for 
which ongoing monitoring and rapid communication by [CONTACT_266085]. Such an event might warrant further investigation in order to characterize and 
understand it.  Depending on the nature of  the event,  rapid communication by  [CONTACT_266086] (e.g., regulators) might also be warranted.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 57  
 The following  events  will be considered  AESIs  in this study:  
• Treatment -emergent  ALT or AST >3 x upper  limit of normal  (ULN)  in combination  with (1) total 
bilirubin >[ADDRESS_323779] and/or (2) clinical jaundice.  
Clinically  significant  laboratory,  ECG, or vital  signs  abnormalities : A laboratory  test or ECG 
abnormality is deemed clinically significant if it meets one or more of the following criteria:  
• Is accompanied  by [CONTACT_12394]  
• Results in a change in study treatment (e.g., study drug interruption or discontinuation, or  
dosage modification)  
• Results  in a medical  intervention  (e.g. treatment)  or a change  in concomitant  therapy  
• Is clinically  significant  in the investigator’s  judgment.  
Study Drug Misuse is defined as intentional use of the investigational product other than as 
directed  or indicated  at any dose  (Note:  this includes  a situation  where  the investigational  product 
is not used as directed at the dose prescribed by [CONTACT_760]).  
Overdose is an intentional or unintentional intake of a dose of the investigational product 
exceeding the pre -specified total daily dose of the product.  
Medication Error is an error made in prescribing, dispensing, administration, and/or use of an 
investigational product.  
 
10.2 OVERALL  SAFETY  PLAN  
 
The safety plan for this study is based on clinical experience with MK -7 in published clinical 
studies.  The anticipated  safety  risks for EPN-701 are outlined  in Section  6.3.4 . Please  refer to the 
EPN-701 Investigator's Brochure for a complete summary of clinical safety information.  
Several  measures  will be taken  to ensure  the safety  of subjects  participating  in this study.  These 
include the pre -specified eligibility criteria (see Section  9.1.1  and Section  9.1.2 ), designed to 
exclude subjects at  higher  risk for  adverse events,  close safety  monitoring of  subjects during the 
study (see Section  9.5), including assessment of the nature, frequency, and severity of adverse 
events (see Section  10.3). 
General safety assessments will consist of monitoring and recording adverse events, including 
SAEs,  AESIs,  and AEs leading  to study  drug discontinuation  (with  or without  withdrawal  from the 
study), performing protocol specified physical examinations, ECGs and safety laboratory 
assessments (including hematology, CMP, and coagulation panel), and measuring vital signs; 
see Table [ADDRESS_323780] and timing of study assessments. During on -treatment study visits, 
applicable  clinical  and laboratory  assessments  will be completed  and reviewed  prior to study  drug 
administration. Adverse events (regardless of relationship to study drug) will be recorded in the 
AE CRF for [ADDRESS_323781] dose  of EPN-701 (until  the EOS  Visit/Day  29), and will be graded 
by [CONTACT_926],  and assessed  for causality.  Serious  adverse  events  (SAEs),  AESIs  and pregnancies 
occurring  during  or within  [ADDRESS_323782] dose  of EPN-701 will be reported  in an expedited  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 58  
 fashion,  as described  in Section  10.4. Any case  of study  drug error,  misuse,  or overdose  will also 
be reported in an expedited fashion (see Section  10.4). 
A SRC  will review  the safety  data accumulated  during  the study  at regular  intervals.  The SRC  will 
be comprised of  the Sponsor’s Medical Monitor, Independent  Medical  Monitor, and the Principal 
Investigator; refer to Section  10.6. 
10.2.1  Dose  Modifications  and Interruptions  due to Adverse  Events  
 
Dose  reduction  of EPN-701 is not permitted  in this study.  
There  are currently  no known  adverse  events  that would  require  interruption  or discontinuation  of 
EPN-701 treatment. However, unanticipated adverse events or other safety findings during the 
trial may warrant interruption or discontinuation of study drug. The acceptable length of 
interruption will depend on agreement between the investigator and the Medical Monitor.  
 
10.3 RECORDING  AND  ASSESSMENT  OF ADVERSE  EVENTS  
 
The investigator is responsible for  ensuring that  all adverse events are recorded on the Adverse 
Event  eCRF  and reported  to the Sponsor  in accordance  with instructions  provided  in this section 
and in Section  10.4 (immediate reporting).  
For each adverse event, the investigator will make an assessment of seriousness (see Section  
10.1 for seriousness  criteria),  severity  (see Section  [IP_ADDRESS] ), and causality  (see Section  [IP_ADDRESS] ) 
on the Adverse Event eCRF.  
10.3.[ADDRESS_323783] 
dose of  study  drug (EOS/Early  Termination Visit)  are to be recorded  on the appropriate Adverse 
Event CRF pages and in source documents.  
Serious adverse  events (SAEs),  AESIs  and pregnancies occurring during or  within [ADDRESS_323784] dose of EPN -701 will also be reported in an expedited fashion, as described in Section  
10.4. SAEs and AESI considered to be related to the study drug by [CONTACT_093], will be 
reported to the Sponsor even if they occurred after the protocol -specified reporting period (i.e., 
more than [ADDRESS_323785] dose of EPN -701). Follow -up of SAEs and AESIs will continue 
until resolution  or until they reach  a chronic/stable  condition.  In the unlikely  event  of a pregnancy 
reported during the study, the event should be followed until pregnancy outcome, i.e. birth or 
termination.  
10.3.[ADDRESS_323786] medical terminology/concepts when recording adverse events 
on the Adverse Event eCRF. Colloquialisms and abbreviations should be avoided.  
Only one adverse  event  term should  be recorded  in the event  field on the Adverse  Event  eCRF.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 59  
 The following  guidelines  should  be observed  when  recording  AEs: 
• Preexisting medical conditions (present at the screening visit): should be recorded on the 
Medical History eCRF. A preexisting medical condition should be recorded as an AE only if 
the frequency or severity worsens during the study.  
• Symptoms of the Disease Under Study: should not be recorded as AEs, as long as they are 
within the normal day -to-day fluctuation or expected progression of the disease. However, 
significant worsening of the symptoms should be recorded as an AE.  
• Diagnosis  vs Symptoms:  Where  possible, a  diagnosis,  rather  than a list of symptoms,  should 
be recorded. If a diagnosis has not been made, then each symptom should be listed 
individually. In addition to untoward AEs, unexpected benefits outside the investigational 
product indication should also be captured on the AE eCRF.  
• Secondary AEs: In general, adverse events that are secondary to other events (e.g., clinical 
sequelae  or cascade  events)  should  be identified  by [CONTACT_262750],  except  for severe  or 
serious secondary events. If it is unclear as to whether the events are associated, each AE 
should be recorded separately on the Adverse Event eCRF.  
• Persistent AEs (events that extends continuously between study visits): should only be 
recorded once, with the highest overserved/reported severity on the Adverse Event eCRF.  
• Recurring AEs (events that resolves between study visits and subsequently recur): each 
recurrence should be recorded as a separate event on the Adverse Event eCRF.  
• Abnormal laboratory values: All clinically significant laboratory test results must be reported 
as AEs. If a clinically significant laboratory abnormality is a sign of a disease or syndrome, 
only the diagnosis should be recorded on the Adverse Event eCRF.  
• Abnormal ECG results: All treatment -emergent clinically significant ECG abnormalities must 
be reported as AEs.  
• Adverse events associated with an incorrect administration (medication error or misuse) or 
overdose of the study drug should be recorded on the Adverse  Event eCRF. Any incorrect 
administration of study drug or study drug overdose should be noted on the Study Drug 
Administration CRF and reported as a protocol deviation.  
• Any occurrence of dialyzer clotting (assessed at each dialysis session) is to be recorded as 
an AE, using the term “clotting of extracorporeal circuit" or equivalent.  
10.3.3  Assessment  of Adverse  Events  
 
[IP_ADDRESS]  Assessment  of Severity  
 
The medical  assessment  of AE severity  is determined  by [CONTACT_266087]:  
• Mild: A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of daily 
living.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 60  
 • Moderate: A type of AE that is usually alleviated with specific therapeutic intervention. The 
event  interferes  with usual  activities  of daily living,  causing  discomfort  but poses  no significant 
or permanent risk of harm to the research subject.  
• Severe: A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
The severity of AEs must be assessed during the course of the event. An event that continues, 
but changes  in severity  over a period  of time should  be captured  once  on the AE eCRF  form,  with 
the highest  severity  reported  though  its duration.  Worsening  of pre-treatment  events  after initiation 
of investigational product, must be recorded as new AEs (for example, if a subject experiences 
mild intermittent dyspepsia prior to dosing of the investigational product, but the dyspepsia 
becomes severe and more frequent after first dose of investigational product has been 
administered, a new AE of severe dyspepsia [with the appropriate date of onset] is recorded on 
the AE eCRF).  
[IP_ADDRESS]  Assessment  of Causality  
 
The causality assessment for each AE must be completed by [CONTACT_093]. The investigator 
should  use medical  judgment,  including  knowledge  of the subject,  the circumstances  surrounding 
the event, and evaluate any potential alternative causes when deciding whether there is a 
reasonable  possibility  that the event  may have  been  caused  by [CONTACT_266088].  If there 
is no valid reason for suggesting a relationship, the AE should be classified as ‘not related’. 
Otherwise,  if there  is any valid reason,  even  if undetermined  or untested,  for suspecting  a possible 
cause -and-effect relationship between the investigational  product and the occurrence of the AE, 
the AE should be assessed as ‘related’. The causality assessment must be documented in the 
source document and the CRF.  
 
Table  [ADDRESS_323787], is plausible pharmacologically, and cannot be explained by 
[CONTACT_9153]. Withdrawal of the 
drug (dechallenge) was followed by [CONTACT_266089]. Recurrence of symptoms on rechallenge (if performed) has 
occurred.  
 
 
Probably 
Related   
 
Yes A clinical event, including laboratory test abnormality, with a 
reasonable  time sequence  to the administration  of the investigational 
product,  unlikely  to be attributed  to concurrent  disease  or other  drugs 
or chemicals. Withdrawal of the drug (dechallenge) was followed by 
[CONTACT_266090]. Rechallenge information is 
not required to fulfil this definition.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323788]’s underlying disease provide plausible explanations for the 
event.  
 
Not Related   
No The event can be readily explained by [CONTACT_11260]’s underlying medical condition, concomitant therapy, or 
accident  and no plausible  temporal  or biologic  relationship  exists 
between the investigational product and the event.  
The investigator’s assessment of the relationship between the AE and the underlying condition 
(including hemodialysis) will also be recorded.  
[IP_ADDRESS]  Assessment  and Documentation  of Outcome  
 
During the study period, resolution of AEs (with dates) should be documented on the AE eCRF 
and in the subject’s medical record to facilitate source data verification.  
The outcome  of AEs must  be recorded  during  the study  on the CRF by [CONTACT_266091]:  
• Recovered/Resolved  
• Recovered/Resolved  with Sequelae  
• Ongoing,  but reached  chronic  or stable  condition  at the last follow -up 
• Fatal  
• Unknown  
10.3.4  Adverse  Event  Follow -up Period  
 
The investigator  should  follow  each  AE until the event  has resolved  to baseline  or normal  status, 
the event is assessed as stable by [CONTACT_093] (no further improvement or worsening of the 
event is expected), the subject is lost to follow -up, or the subject withdraws consent. When 
appropriate, medical  tests and examinations are performed so that resolution of event(s) can  be 
documented.  
Every  effort  should be  made to follow  all SAEs  until a final  outcome can be determined.  
In the unlikely  event  of a pregnancy  reported during the study,  the event  should be followed until 
pregnancy outcome, i.e. birth or termination.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323789]  report  the following  events  to the Sponsor  immediately  (i.e., within  24 hours 
of becoming aware of the event), regardless of their relationship to study drug:  
• SAEs  
• AESIs  
• Pregnancies  
• Medication  errors,  misuses,  and overdoses.  
10.4.2  Reporting  Requirements  for SAEs  and AESIs  
 
[IP_ADDRESS]  Serious  Adverse  Event  Reporting  Timeframe  
 
All SAEs and AESIs (regardless of their relationship to the study drug) occurring from the time 
the subject provided informed consent until [ADDRESS_323790] awareness 
of the event. Thereafter, any SAE(s) or AESI considered “related” to the study drug must be 
reported  to the Pharmacovigilance  Department  within  [ADDRESS_323791] dose of the study drug.  
Preferred  method:  The investigator  should report  these  events  either  by [CONTACT_266092]/Adverse Event of Special Interest Reporting Form to the 
following e -mail address:  
[EMAIL_5126]  
Alternative method: The completed Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form may be faxed to the following designated fax number:  
[PHONE_5513]  
Attention:  Epi[INVESTIGATOR_266038]. Receipt will be 
acknowledged in a timely manner via secure email.  
Electronic  data capture  (EDC)  is the primary  source  for entering  SAE data documented  on source 
documents. However, a back -up SAE Form (and Guidelines) for SAE reporting should be used 
for reporting to the Safety group within the SAE Reporting Guidelines in the event  EDC is down 
or not accessible.  
The investigator must also report new significant follow -up information for these events to the 
Sponsor  immediately  (i.e., no more  than 24 hours  after becoming  aware  of the information).  New 
significant information may include any of the following:  
• Change  in the event’s  outcome  (including  resolution)  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 63  
 • Change  in the diagnosis  
• Development  of new signs  or symptoms  or significant  worsening  in the condition  
• Significant  new test results  
• Change  in causality  based  on new information  
• Other  significant  information  on the clinical  course  of the event.  
Investigators must also comply with local requirements for reporting SAEs to the Institutional 
Review Board (IRB).  
The onset  date of the SAE is the date that symptoms  of the event  began,  and the resolution  date 
is the date the symptoms resolve, or the event is considered to have reached a chronic/stable 
condition.  
Any SAE that results  in the subject’s  death  must  have  fatal checked  as an outcome  with the date 
of death  recorded  as the resolution  date.  For all other  events  ongoing  at time of death  that did not 
contribute to the subject’s death, the outcome should be considered not resolved, without a 
resolution date recorded.  
10.4.[ADDRESS_323792] -partum (or  termination 
of the pregnancy).  
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported to the Sponsor immediately (i.e., no more than 24 
hours  after learning  of the event)  using  the Clinical  Trial Serious  Adverse  Event  Form.  An elective 
abortion is not considered an SAE.  
In addition, if the Investigator determines that the pregnancy meets seriousness criteria, it must 
be reported as an SAE. The test date of the first positive serum/urine HCG test or ultrasound 
result will determine the pregnancy onset date.  
 
10.[ADDRESS_323793] to identify and expeditiously communicate possible  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 64  
 new safety findings to investigators, Institutional Review Boards (IRBs), and the US Food and 
Drug Administration (FDA), as per the applicable regulations and guidelines.  
Reporting  requirements  to the FDA and IRB(s)  will be based  on the investigator's  assessment  of 
causality and seriousness, and the Sponsor’s assessment of the expectedness of the event. 
Expectedness will be evaluated by [CONTACT_266093] (and cumulative event 
frequency observed in the study, as applicable) with the severity and frequency reported in the 
applicable reference document (EPN -701 Investigator’s Brochure).  
 
10.6 SAFETY  REVIEWS  BY [CONTACT_266094] 
 
A SRC  will review  the safety  data accumulated  during  the study  at regular  intervals.  The SRC  will 
be comprised of  the Sponsor’s Medical Monitor, Independent  Medical  Monitor, and the Principal 
Investigator. Further details will be provided in the SRC Charter.  
 
11. STATISTICAL  CONSIDERATIONS  AND  ANALYSIS  PLAN  
 
11.[ADDRESS_323794] on a stable maintenance 
hemodialysis  regimen.  The primary  objective  of the study  is to determine  the safety  and tolerability 
of EPN -701 (administered for two weeks at a daily dose of 10 mg).  
There are no efficacy assessments or endpoints in this study. The primary (safety) endpoint is 
the frequency of treatment -emergent AEs and treatment -emergent AEs assessed as related to 
the study drug. Pharmacokinetic parameters and biomarkers represent secondary and/or 
exploratory endpoints.  
The analysis  populations  are defined  as follows:  
• Safety  population:  all enrolled  subjects  who received  at least  one dose  of study  drug.  
• PK population: all enrolled subjects who received at least one dose of study drug and have 
sufficient plasma concentrations data for PK analysis.  
All analyses will be descriptive. Binary and categorical data will be summarized by [CONTACT_266095].  Continuous  data will be summarized  by [CONTACT_3163],  standard  deviations  (SDs), 
medians, and ranges (minimum, maximum), as appropriate.  
All data will be included  in appropriate  per-subject  listings. 
Planned  analyses  are presented  in the following  sections.  
11.[ADDRESS_323795] exposure.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323796]  DISPOSITION  
 
All enrolled subjects will be accounted for. The number of subjects who enroll, discontinue, or 
complete the study will be listed and summarized. All early treatment discontinuations and 
withdrawals from the study will be summarized by [CONTACT_266096]/withdrawal.  
Time  in trial and treatment  exposure  will also be summarized.  
Protocol deviations and reasons for granting waivers (as applicable) will be categorized and 
provided in by -subject listings.  
 
11.4 DEMOGRAPHIC  AND  BASELINE  CHARACTERISTICS  
 
Demographic variables such as age, sex, race/ethnicity, and other relevant baseline 
characteristics will be summarized using means, SDs, medians, and ranges for continuous 
variables and proportions for categorical variables, as appropriate.  
The baseline value of any variable will be defined as the last available value prior to the first 
administration of the study drug.  
 
11.[ADDRESS_323797]  one dose  of the study  drug 
(EPN -701).  
Safety will be  assessed  through  summaries  of AEs, changes  in safety laboratory  test results, 
changes in vital signs, ECG parameters, and study drug exposures.  
The primary safety endpoint is the frequency of treatment -emergent AEs (defined as any AE 
with an onset  between  the first dose  of the study  drug and the last study  visit, or  any AE with an 
onset  prior to first  dose that  increases in severity  or frequency  after the first  dose of  study  drug) 
and treatment -emergent AEs assessed as related to the study drug. Adverse events include 
both clinical events and laboratory abnormalities that are assessed as clinically significant.  
Secondary  safety  endpoints  include:  
• Frequency  of SAEs,  AEs leading  to study  drug discontinuation,  and AESIs  
• Changes  from baseline  in safety  laboratory  parameters  
• Changes  from baseline in  vital signs  measurements  
• Changes  from baseline  in ECG  parameters.  
11.6.1  Adverse  Events  
 
All AEs will  be coded  using the current  version of  the Medical  Dictionary  for Regulatory  Activities 
(MedDRA) and will be included in per -subject listings. In addition, treatment -emergent AEs  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 66  
 (defined as any AE with an onset between the first dose of the study drug and the last study 
visit, or any AE with an onset prior to first dose that increases in severity or frequency after the 
first dose of study drug) will be summarized in frequency tables, by [CONTACT_141588]  (SOC)  and by [CONTACT_266097] (PT),  regardless  of the investigator -determined  relationship 
to study  drug.  For each  subject,  if there are multiple occurrences of  the same AE,  the maximum 
severity reported will be used in the summaries.  
Adverse  events  assessed  as related  to the study  drug will be summarized in  a similar  manner.  A 
summary of AEs by [CONTACT_266098].  
The following  treatment -emergent  AEs will also be summarized:  
• Adverse  events  leading  to permanent  discontinuation  of study  drug (with  or without 
withdrawal from the study)  
• Adverse  events  leading  to dose  interruption  
• Serious  adverse  events  
• AESIs  
• Deaths.  
11.6.2  Concomitant  Medications  
 
Concomitant Medications: All concomitant medications will be coded using the most current 
version of the World Health Organization (WHO) Drug Dictionary and will be included in per - 
subject listings.  
11.6.3  Safety  Laboratory  Parameters  
 
Laboratory parameters will be summarized at each time point measured using descriptive 
statistics,  including  means,  SDs,  medians,  and ranges,  as appropriate.  Change  from baseline  will 
be summarized similarly, with 95% confidence intervals (CIs) for each change. Shift tables may 
also be provided,  if warranted  by [CONTACT_26739].  All safety  laboratory  data will be included  in appropriate 
per-subject  listings,  along  with reference  ranges,  and indication  of clinically  significant  departures 
from the respective reference ranges.  
Clinically  significant  laboratory  abnormalities  will be analyzed  as part of the analysis  of AEs. 
11.6.4  ECG  Changes  and Abnormalities  
 
ECG  parameters:  will be included  in appropriate  per-subject  listings.  In addition,  a tabulated 
summary of the following parameters will be provided:  
• number  (%) of subjects  with QT interval  and QT interval  corrected  for heat rate using  the 
Fridericia’s formula (QTcF) >500 msec  
• changes  from baseline  of >30 msec  and of >60 msec  in QT and QTcF  values  
• number  (%) of subjects  with clinically  significant  ECG  abnormalities.  
Clinically  significant  ECG  abnormalities  will be analyzed  as part of the analysis  of AEs. 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323798] 
sufficient plasma concentrations data for PK analysis.  
EPN-701 plasma concentration will be measured at specific timepoints (see Table 1 ), tabulated 
and summarized by [CONTACT_266099]. Descriptive statistics for plasma concentrations and 
PK parameters will include arithmetic means and SDs, geometric means and coefficients of 
variation, medians, and ranges, as appropriate.  
In addition, depending on the plasma concentrations observed at the pre -specified time -points, 
the following PK parameters may be summarized using the same descriptive statistics as for 
plasma concentrations:  
• Cmax [ng/mL]  
• Tmax [hr] 
• AUC 0-24 [hr×ng/mL].  
 
11.8 BIOMARKER  ANALYSES  
 
Pre-defined  biomarker  endpoints  include:  
• Plasma  levels  of the following  biomarkers  on Day 15 (end-of-treatment)  and Day 22 compared 
to baseline:  
o Uncarboxylated  MGP  
o Uncarboxylated  osteocalcin  
o Activated  Protein  C 
o PI[INVESTIGATOR_266018] -II protein.  
Exploratory  biomarker  endpoints  include:  
• Plasma  levels  of the following  biomarkers  on Day 15 (end-of-treatment)  and Day 22 compared 
to baseline: osteoprotegerin, Fetuin A, hs-CRP, and Time to Formation of Secondary 
Calciprotein Particles (T -[ADDRESS_323799]), including CPP size.  
Biomarkers  will be summarized  in a similar  manner  as described  for safety  laboratory  parameters, 
with a descriptive summary provided for each assessment time -point along with changes from 
baseline. Depending of the distribution of the biomarkers, transformations to minimize skew  and 
outliers may be performed.  
 
11.9 SUBGROUP  ANALYSES  
 
No subgroup  analyses  are planned.  
 
11.10  INTERIM  ANALYSIS  
 
No interim analyses  are planned.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323800] data collected during the study will be recorded on eCRFs, which will be completed 
through use of a Sponsor -designated EDC system. Sites will undergo appropriate training and 
will receive a manual with instructions on adequate eCRF completion.  
All eCRFs should be completed by [CONTACT_25755], trained site staff, and should be reviewed and 
electronically  signed  and dated  by [CONTACT_093].  eCRFs  will be submitted  electronically  (via the 
EDC system) to the Sponsor (or designee).  
At the end of the study,  the investigator  will receive  all subject  data for his or her site in a readable 
format (e.g., on a compact disc) that must be kept with the study records.  
 
12.[ADDRESS_323801] documented requirements for 
completeness, accuracy (including verification of the data), reliability, and consistent intended 
performance. Any changes to the data will be captured in a readable audit trail. Documentation 
will be kept indicating  the individual  tasks  and the personnel  authorized  to perform  them.  The data 
will be checked for completeness, accuracy, and logic; any missing, illegible  or illogical data will 
be queried. Responses to data queries will be entered following the same process as for the 
original  eCRF.  The investigator  must  review  and approve  all eCRF  entries  and responses  to data 
queries.  
Accurate and reliable data collection will also be assured by [CONTACT_266100], the drug dispensing log and study drug supplies by 
[CONTACT_266101]  (CRA,  also referred  to as study  monitor);  refer to 
Section  12.3. 
 
12.3 SITE  MONITORING  AND  AUDITS  
 
The investigator will permit Sponsor representatives, CRAs (study monitors), health authorities; 
and the reviewing  IRB to inspect  facilities  and records  relevant  to this study,  including  direct  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 69  
 access to source data and documents, study drug and related accountability records, and the 
study -specific Site Master File (SMF).  
Site visits will be conducted by [CONTACT_266102] (CRA) at regular 
intervals throughout the study, for inspection of study data, subjects’ medical records, eCRFs, 
and study drug supplies.  
The Investigator must be available during the monitoring visits, as needed, and cooperate with 
the CRA to ensure that any problems detected during monitoring are promptly resolved.  
12.3.1  Source  Documentation  
 
Source documents include, but are not limited to: clinic charts, dialysis flowsheets, subject files, 
hospi[INVESTIGATOR_1097], laboratory notes, subject -reported events and outcomes, ECG printouts, 
evaluation checklists and schedules, pharmacy dispensing records, data recorded from 
automated instruments, X -rays, microfilm, and records kept at pharmacies and laboratories 
involved in a clinical trial.  
Source  documents  must  not be obliterated  or destroyed  and must  be retained  for at least  [ADDRESS_323802]  access  to applicable  source  documents  and reports  for 
trial-related monitoring, Sponsor audits (as applicable), and inspection by [CONTACT_266103].  
 
12.[ADDRESS_323803] of this study (including eCRFs, ICFs, ECG, 
and laboratory test results, source documents, and study -specific SMF) and the distribution of 
study drug (such as study drug inventory and accountability records), must be retained by [CONTACT_11087]  [INVESTIGATOR_25653]  [ADDRESS_323804] to local regulations.  
No records may be disposed of without the written approval of the Sponsor. Written notification 
should be provided to the Sponsor prior to transferring any records to another party or moving 
them to another location.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 70  
 13. ETHICAL  CONSIDERATIONS  
 
13.1 REGULATORY  COMPLIANCE  
 
This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical 
Practice,  the principles  of the Declaration  of Helsinki,  and with US FDA regulations  and applicable 
local, state, and federal laws. The study will also comply with the requirements of the ICH E2A 
guideline  (Clinical  Safety  Data  Management:  Definitions  and Standards  for Expedited  Reporting).  
 
13.2 INFORMED  CONSENT  
 
The study  will be conducted  in accordance  with FDA Code  of Federal  Regulations  (CFR)  Title 21, 
Part 50, Subpart B -Informed Consent of Human Subjects and the applicable local IRB 
requirements.  
The investigator must obtain written informed consent from each prospective subject  or they 
legally authorized representative after adequate explanation of the aims, methods, anticipated 
benefits, and potential hazards of the study, and before any study -related procedures, 
assessments,  treatments,  or protocol -required  changes  in the subject’s  ongoing  management  can 
be made. The clinical records for each subject should document the informed consent process 
and that written informed consent was obtained prior to participation in the study.  
The consent  forms  will be revised  each  time there  are changes  to study  procedures  or when  new 
information becomes available that may affect the willingness of the subject to participate. The 
final revised IRB -approved consent form(s) must be provided to the Sponsor for health authority 
submission purposes.  
Subjects  participating  in the study  must  be re-consented  to the most  current  version  of the consent 
form, according to the applicable local law and IRB policy. A copy of each signed consent form 
must  be provided to  the subject  or the subject’s legally  authorized representative.  All signed  and 
dated consent forms must remain in each subject’s study file or in the site file and must be 
available for verification by [CONTACT_9534].  
Subject authorization to allow use and disclosure of personal health information in compliance 
with the U.S. Health  Insurance  Portability  and Accountability  Act (HIPAA)  of [ADDRESS_323805]  
 
The study  will adhere  to CFR Title 21, Part 56 (Institutional  Review  Boards).  
This protocol,  the consent  form,  and any accompanying  material  provided  to the subject  (such  as 
subject information sheets or descriptions of the study used to obtain informed consent) as well 
as any advertising or compensation given to the subject, will  be submitted by [CONTACT_266104], and must  be reviewed  and approved  by [CONTACT_266105].  The 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323806]  also submit  any protocol  amendments  for IRB approval  in accordance  with 
local procedures and regulatory requirements. Additional documents submitted to the IRB will 
include (as applicable): written IND safety reports or other safety -related communications from 
the Sponsor,  and reports  on major  protocol  deviations.  Investigators  are responsible  for ensuring 
that such reports are reviewed and processed in accordance with FDA requirements and the 
policies and procedures established by [CONTACT_266106]’s study file.  
 
13.[ADDRESS_323807] 
identification (ID) number at enrollment. Throughout the study, participating subjects will be 
referred to using their study ID number, and initials. Subject names or other personal identifiers 
are not included  in data sets or any other  documents  that are transmitted  to the Sponsor  or CRO 
designee.  
Data  generated  by [CONTACT_266107],  Sponsor  monitors,  representatives,  and collaborators, 
and the reviewing IRB(s), as appropriate.  
Given the complexity and exploratory nature of the analyses, data derived from exploratory 
biomarker specimens will generally not be provided to subjects unless required by [CONTACT_2371].  
 
14. STUDY  DOCUMENTATION  
 
14.[ADDRESS_323808] be obtained  before implementation of any  changes, except (1) 
changes necessary to eliminate an immediate hazard to subjects or (2) administrative changes 
(e.g., change in contact [CONTACT_3031]).  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323809] safety 
and/or data integrity to the Sponsor and to the IRB in accordance with the IRB policies and 
procedures.  
The Sponsor  will review  each  protocol  deviation  and assess  whether  any require  reporting  to the 
FDA (e.g. deviations representing a serious breach of Good Clinical Practice guidelines).  
Requests to waive protocol  eligibility criteria, will  not be approved in this study. After the subject 
is enrolled, any protocol exemption request must be approved by [CONTACT_1034]/Medical Monitor 
before it can be implemented.  
 
14.[ADDRESS_323810] related to the study to the 
Sponsor prior to submission for publication or presentation. Authorship will be determined by 
[CONTACT_266108].  
Any inventions and resulting patents or improvements originating from the use of data from this 
study will become and remain the exclusive and unburdened property of the Sponsor.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 73  
 15. REFERENCES  
 
Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, Vermeer C. The role of 
menaquinones (vitamin K2) in human health. British Journal  of Nutrition. 2013;110(08):1357 -68. 
doi:10.1017/s0007114513001013.  
Brandenburg VM, Evenepoel P, Floege J, et al.; ERA -EDTA Working Group on CKD -MBD and 
EUCALNET.  Lack  of evidence  does  not justify  neglect:  how can we address  unmet  medical  needs 
in calciphylaxis? Nephrol Dial Transplant. 2016 Aug;31(8):1211 -9. doi: 10.1093/ndt/gfw025  
Brandenburg  VM, Kramann  R, Rothe  H, et al. Calcific  uraemic  arteriolopathy  (calciphylaxis):  data 
from a large nationwide registry. Nephrol Dial Transplant. 2017 Jan 1;32(1):126 -132. doi: 
10.1093/ndt/gfv438.  
Booth S, Suttie JW. Dietary intake and adequacy of vitamin K. Journal of Nutrition. 
1998;128(5):785 -8. 
Caluwe R, Vandecasteele S, Vlem BV, Vermeer C, Vriese ASD. Vitamin K2 supplementation in 
haemodialysis patients: a randomized dose -finding study. Nephrology Dialysis Transplantation . 
2014; 29(7):1385 -1390. doi:10.1093/ndt/gft464.  
Caspers M, Czogalla KJ, Liphardt K, et al. Two enzymes catalyze vitamin K 2,3 -epoxide 
reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 
is highly expressed in brain. Thromb Res. 2015 May;135(5):977 -83. doi: 
10.1016/j.thromres.2015.01.025.  
Cranenburg EC, Schurgers LJ, Uiterwijk HH, et al. Vitamin K intake and status are low in 
hemodialysis patients. Kidney Int. 2012 Sep;82(5):605 -10. doi: 10.1038/ki.2012.191.  
Cockayne S, Adamson J, Lanham -New S, et al. Vitamin K and the prevention of fractures: 
systematic review and meta -analysis of randomized controlled trials. Arch Intern Med. 
2006;166:1256 –1261.  
Crowther MA, Donovan D, Harrison L, et al. Low -dose oral vitamin K reliably reverses over - 
anticoagulation due to warfarin. Thromb Haemost 1998;79:[ADDRESS_323811] of 
menaquinone -7 supplementation on circulating species of matrix Gla protein. Atherosclerosis . 
2012; 225(2):397 -402. doi:10.1016/j.atherosclerosis.2012.09.019.  
Delanaye P, Krzesinski J -M, Warling X, et al. Dephosphorylated -uncarboxylated Matrix Gla 
protein  concentration  is predictive  of vitamin  K status  and is correlated  with vascular  calcification 
in a cohort of hemodialysis patients. BMC Nephrol BMC Nephrology. 2014;15(1):145. 
doi:10.1186/1471 -2369 -15-145. 
Elliott  MJ, Booth  SL, Hopman  WM, Holden  RM. Assessment  of potential  biomarkers  of subclinical 
vitamin K deficiency in patients with end -stage kidney disease. Can J Kidney Health Dis. 2014 
Jun 24;1:13. doi: 10.1186/2054 -3581 -1-13. 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 74  
 European Food Safety Authority, Panel on Dietetic Products, Nutrition and Allergies. Scientific 
Opi[INVESTIGATOR_1649]: Vitamin K2 added for nutritional purposes in foods for particular nutritional uses, food 
supplements  and foods  intended  for the general  population  and vitamin  K2 as a source  of vitamin 
K added for nutritional purposes to foodstuffs, in the context of Regulation (EC) No. 258/971. 
EFSA J. 2008;822:1 –31. 
Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, 
Inhibitors  and Inducers.  Last Updated:  11/14/2017.  Available  at: 
https:// www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteraction  
slabeling/ucm093664.htm  
Gallieni  M, Fusaro  M. Vitamin  K and cardiovascular  calcification  in CKD: is patient 
supplementation on the horizon? Kidney Int. 2014 Aug;86(2):232 -4. doi: 10.1038/ki.2014.24.  
Gast G, Roos ND, Sluijs I, et al. A high menaquinone intake reduces the incidence of coronary 
heart disease. Nutrition, Metabolism and Cardiovascular Diseases . 2008; 19(7):504 -510. 
doi:10.1016/j.numecd.2008.10.004.  
Geleijnse  JM, Vermeer  C, Grobbee  DE, Schurgers  LJ, Knapen  MH, van der Meer  IM, Hofman  A, 
Witteman JC.  Dietary  intake of  menaquinone is associated with a reduced risk of  coronary  heart 
disease: the Rotterdam Study. J Nutr . 2004: 134(11):3100 -5. 
Himmelfarb J, McMonagle E. Manifestations of Oxidant Stress in Uremia. Blood Purif. 
2001;19:200 -5. 
Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl 
formation in chronic renal failure. Kidney International, 2000;58:2571 -78. 
Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL. Vitamins K and D Status in 
Stages 3 -5 Chronic Kidney Disease. Clin J Am Soc Nephrol. 2010 Apr;5(4):590 -7. doi: 
10.2215/CJN.06420909.  
ICH Harmonised Tripartite Guideline Clinical Safety Data Management: Definitions and 
Standards for Expedited Reporting E2A Current Step 4 version; dated 27 October 1994.  
Inaba N, Sato T, Yamashita T. Low -Dose Daily Intake of Vitamin K 2(Menaquinone -7) Improves 
Osteocalcin γ -Carboxylation: A Double -Blind, Randomized Controlled Trials.  Journal of 
Nutritional Science and Vitaminology . 2015;61(6):471 -480. doi:10.3177/jnsv.61.471.  
Institute of Medicine (IOM), Food and Nutrition Board. Vitamin K. In: Dietary Reference Intakes 
for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, 
Molybdenum, Nickel, Silicon, Vanadium and Zinc. Washington, DC:National Academy Press; 
2001:162 –196. As cited in: Marles et al. 2017 . 
Jahnen -Dechent,  W., A. Heiss,  C. Schafer  and M. Ketteler  (2011).  "Fetuin -A regulation  of calcified 
matrix metabolism." Circ Res 108(12): 1494 -1509.  
Janigan DT, Hirsch DJ, Klassen GA, Macdonald AS. Calcified subcutaneous arterioles with 
infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failure American Journal of 
Kidney Diseases 2000;35(4):588 -97. 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 75  
 Juanola -Falgarona  M, Salas -Salvadó  J, Martínez -González  MÁ, et al. Dietary  intake  of vitamin  K 
is inversely associated with mortality risk. J Nutr. 2014 May;144(5):743 -50. doi: 
10.3945/jn.113.187740.  
Kaneki  M, Hedges  SJ, Hosoi  T, et al. Japanese  fermented  soybean  food as the major  determinant 
of the large geographic difference in circulating levels of vitamin K2. Nutrition . 2001; 17(4):315 - 
321. doi:10.1016/s0899 -9007(00)[ZIP_CODE] -2. 
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO [ADDRESS_323812]. 
2013;3:1 -150. 
Knapen MHJ, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three -year low -dose 
menaquinone -7 supplementation helps decrease bone loss in healthy postmenopausal women. 
Osteoporosis International . 2013; 24(9):2499 -2507. doi:10.1007/s00198 -013-[ADDRESS_323813]. 2015 May;113(5):1135 -44. doi: 10.1160/TH14 -08-0675.  
Marlar RA, Gausman JN. Assessment of Hereditary Thrombophilia: Performance of Protein C 
(PC) Testing. Methods Mol Biol. 2017;1646:145 -151. doi: 10.1007/978 -1-4939 -7196 -1_11.  
Marles RJ, Roe AL, Oketch -Rabah HA. US Pharmacopeial Convention safety evaluation of 
menaquinone -7, a form of vitamin K. Nutr Rev. 2017 Jul 1;75(7):553 -578. doi: 
10.1093/nutrit/nux022.  
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: 
evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 2):S1 -S266.  
National Center for Biotechnology Information. PubChem Compound Database; CID=5287554, 
https://pubchem.ncbi.nlm.nih.gov/compound/5287554 (accessed Dec 7, 2017).  
Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic 
review. Clin J Am Soc Nephrol. 2008 Jul;3(4):1139 -43. doi: 10.2215/CJN.00530108.  
Nigwekar SU, Zhao S, Wenger J, et al. A Nationally Representative Study of Calcific Uremic 
Arteriolopathy Risk Factors. J Am Soc Nephrol. 2016 Nov;27(11):3421 -9. 
Pasch, A., G. A. Block, M. Bachtler, E. R. Smith, W. Jahnen -Dechent, S. Arampatzis, G. M. 
Chertow,  P. Parfrey,  X. Ma and J. Floege  (2017).  "Blood  Calcification  Propensity,  Cardiovascular 
Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial." Clin J Am Soc 
Nephrol 12(2): 315 -322. 
Pi[INVESTIGATOR_266039], Morton  AR, Boffa  MB, et al. Subclinical  vitamin  K deficiency  in hemodialysis  patients. 
Am J Kidney Dis. 2007 Mar;49(3):432 -9. 
Price, P. A., H. H. June, J. R. Buckley and M. K. Williamson (2001). "Osteoprotegerin inhibits 
artery  calcification induced by  [CONTACT_266109] D." Arterioscler Thromb Vasc Biol  21(10): 
1610 -1616.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 76  
 Pucaj  K, Rasmussen H, Møller M, Preston T. Safety and toxicological evaluation of a synthetic 
vitamin K2, menaquinone -7. Toxicol Mech Methods. 2011 Sep;21(7):520 -32. 
doi:10.3109/15376516.2011.568983.  
Ravishankar B, Dound YA, Mehta DS, et al. Safety assessment of menaquinone -7 for use in 
human nutrition. J Food Drug Anal. 2015 Mar;23(1):99 -108. doi: 10.1016/j.jfda.2014.03.001.  
Scheiber D, Veulemans V, Horn P, et al. High -Dose Menaquinone -7 Supplementation Reduces 
Cardiovascular Calcification in a Murine Model of Extraosseous Calcification. Nutrients. 
2015;7(8):6991 -7011. doi:10.3390/nu7085318.  
Schlieper G, Westenfeld R, Krüger T, et al. Circulating nonphosphorylated carboxylated matrix 
gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011 Feb;22(2):387 -95. doi: 
10.1681/ASN.[PHONE_5514].  
Schurgers  LJ, Barreto DV, Barreto FC, et  al. The Circulating Inactive Form of Matrix  Gla Protein 
Is a Surrogate  Marker  for Vascular  Calcification  in Chronic  Kidney  Disease:  A Preliminary  Report. 
Clin J Am Soc Nephrol. 2010 Apr;5(4):568 -75. doi: 10.2215/CJN.07081009.  
Schurgers LJ, Spronk HMH, Skepper JN et al. Post -translational modifications regulate matrix 
Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J 
Thromb Haemost 2007 a;5:2503 –2511.  
Schurgers LJ, Teunissen KJF, Hamulyak K, et al. Vitamin K -containing dietary supplements: 
comparison of synthetic vitamin K1 and natto -derived menaquinone -7. Blood. 
2007 c;109(8):3279 -83. doi:10.1182/blood -2006 -08-040709.  
Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K -dependent carboxylation of matrix Gla - 
protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013;19(4):217 -26. 
doi:10.1016/j.molmed.2012.12.008.  
Schurgers  LJ, Vermeer C. Differential lipoprotein transport pathways of K -vitamins in healthy 
subjects.  Biochim  Biophys  Acta.  2002  Feb 15;1570(1):27 -32. doi:10.1016/s0304 -4165(02)[ADDRESS_323814]. 
2008;100(4):530 -47. 
Siltari  A, Wickholm N,  Kivimäki  AS, et al. Effects  of Vitamin  K-1 and Menaquinone -7 on Vascular 
Function and Blood Pressure in Warfarin -Induced Calcification -Model in Rats. Pharmacology & 
Pharmacy. 2014; 05(12):1095 -1105. doi:10.4236/pp.2014.512119.  
Stockler -Pi[INVESTIGATOR_266040], Saldanha  JF, Yi D, Mafra  D, et al. The uremic  toxin  indoxyl  sulfate  exacerbates 
reactive oxygen species production and inflammation in 3T3 -L1 adipose cells. Free Radic Res. 
2016;50(3):337 -44. doi: 10.3109/10715762.2015.1125996.  
Theuwissen  E, Smit E, Vermeer  C. The  Role of Vitamin  K in Soft-Tissue  Calcification.  Advances 
in Nutrition: An International Review Journal . 2012; 3(2):166 -173. doi:10.3945/an.111.001628.  
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  [ADDRESS_323815] DW. Functional study of the vitamin K cycle in mammalian 
cells. Blood 2011;117(10):2967 -74. doi: 10.1182/blood -[ADDRESS_323816]  2013;11:1556 –64. J Thromb  Haemost.  2013  Aug;11(8):1556 -64. doi: 10.1111/jth.[ZIP_CODE].  
Tie JK, Stafford DW. Structural and functional insights into enzymes of the vitamin K cycle. J 
Thromb Haemost. 2016 Feb;14(2):236 -47. doi: 10.1111/jth.[ZIP_CODE].  
US Food and Drug Administration.  21 CFR Part  101. Food labeling:  revision of  the Nutrition and 
Supplement Facts Labels; Final Rule. Docket no. FDA –2012 –N–1210, RIN 0910 –AF22. Fed 
Regist. 2016;81:[ZIP_CODE] –[ZIP_CODE]. As cited in Marles et al. 2017 . 
US National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Label 
Database (DSLD). Bethesda, MD: National Institutes of Health, Office of Dietary Supplements. 
https://ods.od.nih.gov/Research/Dietary_Supplement_Label_Database.aspx.  Updated 
September 2016. Last accessed December 15, 2017.  
Vissers LET,  Dalmeijer  GW, Boer  JMA,  Verschuren  WMM,  Schouw YTVD,  Beulens JWJ.  Intake 
of Dietary Phylloquinone and Menaquinones and Risk of Stroke. Journal of the American Heart 
Association . 2013;2(6). doi:10.1161/jaha.113.000455.  
Vitamin  K2 Monograph.  Alternative  Medicine  Review  2009;14(3):284 -93. 
Walther B, Karl JP, Booth SL, Boyaval P. Menaquinones, Bacteria, and the Food Supply: The 
Relevance of Dairy and Fermented Food Products to Vitamin K Requirements. Adv Nutr. 2013 
Jul 1;4(4):463 -73. doi: 10.3945/an.113.003855.  
Watanabe H, Miyamoto Y, Honda D, et al. P -Cresyl  sulfate causes renal  tubular cell damage by 
[CONTACT_266110].  Kidney  Int. 2013  Apr;83(4):582 -92. doi: 
10.1038/ki.2012.448.  
Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional 
vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012, 
59(2):186 -195. 
Westhofen P, Watzka M, Marinova M, et al. Human vitamin K 2,3 -epoxide reductase complex 
subunit 1 -like 1 (VKORC1L1) mediates vitamin K -dependent intracellular antioxidant function. J 
Biol Chem. 2011 Apr 29;286(17):[ZIP_CODE] -94. doi: 10.1074/jbc.M110.210971  
Wilmer WA, Magro CM. Calciphylaxis: Emerging Concepts in Prevention, Diagnosis, and 
Treatment. Semin Dial. 2002 May -Jun;15(3):172 -86. 
Wollina  U. Update on cutaneous calciphylaxis. Indian J Dermatol. 2013 Mar;58(2):87 -92. doi: 
10.4103/0019 -5154.108026.  
World  Health  Organization  and Food  and Agriculture  Organization  of the United  Nations.  Vitamin  
K. In: Vitamin  and Mineral  Requirements  in Human  Nutrition.  2nd ed. Geneva,  Switzerland:  World 
Health Organization; 2004:108 -129. As cited in: Marles et al. 2017 . 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 78  
 
16. APPENDIX  1 - DEFINITION  AND  CLASSIFICATION  OF CHRONIC  
KIDNEY DISEASE (CKD)  
 
Chronic  Kidney  Disease  
Chronic  Kidney  Disease  (CKD)  is defined  as abnormalities  of kidney  structure  or function  (defined 
as a glomerular  filtration  rate [GFR]  <60 mL/min/1.73  m2), present  for ≥3 months,  with implications 
for health ( KDIGO, 2012 ). Criteria for CKD include are detailed in the following table.  
Table  A. Criteria  for Chronic  Kidney  Disease  (either  of the following  present  for ≥3 
months)  
 
Source: The  National  Kidney  Foundation  (NKF)  Kidney Disease  Improving  Global  Outcomes  (KDIGO)  2012  Clinical 
Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 2012  
Among  patients  with CKD,  the stage  of disease  is determined  based  on the level of kidney  function 
(with higher stages representing lower GFR levels), irrespective of diagnosis. The KDOQI 
classification of CKD is presented in Table A , and further elaborated in Table B . 
Table  B. GFR  Categories  in Chronic  Kidney  Disease  
 
Source: The  National  Kidney  Foundation  (NKF)  Kidney Disease  Improving  Global  Outcomes  (KDIGO)  2012  Clinical 
Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 2012  
Note: GFR  categories G1  through  G5 correspond  to previous  stratification  into Stages  1 through  5. 
Source:  NKF KDOQI  Guidelines  
 
Kidney  failure  
Kidney  failure is defined as GFR <15  ml/min/1.73  m2 (GFR  category  G5). Kidney  failure leads to 
the commonly recognized symptoms of  uremia. The need for treatment of chronic kidney failure 
with dialysis and/or kidney transplantation arises in 1% of patients with CKD ( KDIGO, 2012 ). 
EPI[INVESTIGATOR_266014],  INC. CONFIDENTIAL  
Protocol  Number:  EPN-701-001, Amendment  3 79  
 End-stage  renal  disease  
End-stage  renal  disease  (ESRD)  includes  patients  treated  by [CONTACT_266111], 
irrespective of the level of GFR ( KDOQI, 2002 ). 
Note:  The current  KDIGO  guidelines  on CKD  (KDIGO,  2012 ) do not include  a definition  of ESRD.  